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Abstract 
 
Psoriasis is a common chronic inflammatory skin condition. Several key mediators have 
been identified to play a role in the pathogenesis of this disease including PPAR! and 
STAT3. PPAR! is a member of the Peroxisome Proliferator Activator Receptor family 
and has been implicated in psoriasis, as supported by microarray and 
immunohistochemical data. Based on these data, we sought to generate an in vivo 
model that overexpresses PPAR! specifically in the epidermis. A model was available 
that we sought to characterise. This model, following induction with a specific PPAR! 
ligand, results in a psoriasis-like skin phenotype, accompanied by immune system 
activation and gene dysregulation. In addition, STAT3 is highly activated in this animal 
model in the suprabasal layer of murine skin, which is an important feature of psoriasis. 
The inhibition of STAT3 inhibits phenotype development in this model. In addition, in 
this model, interferon response genes are downregulated, which contrasts with human 
psoriasis. However this downregulation is partially reversed following treatment with 
WP1066 as measured by the expression of IFI27, suggesting that activation of STAT3 
is at least partially responsible for IFN target gene repression. This data show that 
epidermis-specific overexpression of PPAR! results in a psoriasis-like phenotype, 
suggesting a central role for PPAR! in psoriasis. STAT3 is also highly activated in this 
model, supporting the current evidence that STAT3 plays a role in psoriatic disease. 
Together, this suggests that STAT3 activation occurs downstream of PPAR! activation 
and indicates that inhibition of PPAR! may be effective for the treatment of psoriasis. 
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Chapter 1: Introduction 
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1. Introduction 
 
Psoriasis is a common inflammatory skin disease, affecting around 25 million people in 
Europe and America (Lowes et al 2007, Westergaard et al 2003), and is one of the most 
common immune-mediated skin diseases in adults. In order to develop novel therapies 
for the disease it is vital to understand molecular events underlying its pathogenesis. 
 
To date, there have been myriad studies utilising different approaches to uncover the 
mechanisms underlying psoriasis disease development, including cell culture (in vitro), 
animal models (in vivo), and genetic studies of patients. This has identified a number of 
different genes and pathways that may contribute to disease progression, two of which 
will be discussed in detail in this thesis, Peroxisome Proliferator Activator Receptor ! 
(PPAR !), and Signal Transducers and Activators of Transcription 3 (STAT3).  
 
1.1 Skin Physiology: Structure And Function 
 
The skin is the body’s outermost defence against invading pathogens and microbes. The 
skin plays a vital role in the overall homeostasis of the body via the excretion of salts, 
water and organic wastes, maintenance of normal body temperature, storage of lipids 
and synthesis of vitamin D3. It is a highly complex structure, composed of several 
different cells types, which form into different layers. There are three distinct layers, the 
epidermis, the dermis and the subcutaneous layer.  
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1.1.1 The Epidermis 
 
The epidermis is the uppermost of the three layers in the skin and can be further 
subdivided into 5 layers, the basal layer, spinous layer, granular layer, stratum lucidium 
and stratum corneum. The innermost layer is the basal layer and is the only layer that 
has the capacity for DNA synthesis and mitosis (Fuchs 1990). Cells from the basal 
layer, following an as yet unidentified trigger, commit to terminal differentiation and 
begin their journey to the surface of the skin. During this journey, the basal cell will 
undergo changes that ultimately result in the formation of dead, flattened, and 
enucleated cells that are expendable and are continually replaced by cells from the 
lower layers undergoing the same process. 
 
The basal layer is the only layer where proliferating keratinocytes are located, which 
adhere to the underlying basement membrane (Pincelli and Marconi 2010). Cells in the 
basal layer detach from the basement membrane at set intervals and withdraw from the 
cell cycle and initiate terminal differentiation. Following commitment to terminal 
differentiation, keratinocytes progress through three different stages, which form the 
different layers of the skin, the spinous, granular and finally the stratum corneum 
(Pincelli and Marconi 2010). The molecular mechanisms that drive this process are 
complex and involve many different genes. This process is still poorly understood 
(Blanpain and Fuchs 2009).  
 
The cells in the basal layer include keratinocyte stem cells. There are 3 different types 
of keratinocyte stem cells present in the epidermis which are found at different locations 
therein: interfollicular epidermis, hair follicles, and sebaceous glands (Pincelli and 
Marconi 2010). The interfollicular stem cells are principally involved with the 
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regeneration of the epidermis, which is dependent on the proliferation of these cells. 
Stem cells actually divide relatively infrequently. When they do divide, they produce a 
stem cell daughter cell and a rapidly dividing non-stem committed progenitor cell, 
termed a transit amplifying cell (Pincelli and Marconi 2010). Transit amplifying cells 
only divide a relatively small number of times before they commit to terminal 
differentiation in the suprabasal layer.  
 
The intracellular cytoskeleton of basal cells is composed of a dispersed but extensive 
network of keratin filaments, mainly keratin 5 and keratin 14 (Fuchs 1990). Connecting 
these cells are structures, which are also present in the spinous layer, called 
desmosomes. These are calcium-activated membrane junctions that help connect the 
cells in the basal layer to form a three-dimensional lattice (Franke et al 1987). As the 
cells migrate upwards towards the surface, different genes that enable differentiation are 
activated. When cells reach the spinous layer, they are principally involved in the 
synthesis of two different keratins, mainly K1 and K10, which form cytoskeletal 
filaments that aggregate into thin bundles (Eichner et al 1986). It is in the spinous layer 
that keratinocytes begin to synthesise involucrin, an envelope protein that is deposited 
on the inner surface of the plasma membrane of each cell (Rice and Green 1979). 
Synthesised at the same time are membrane-coating granules, which fuse with the 
plasma membrane and release lipids into the intercellular space of granular and stratum 
corneum cells (Fuchs 1990, Swartzendruber et al 1989).  
 
Once cells from the spinous layer migrate into the granular layer, production of keratin 
and envelope proteins is ceased and cells begin to produce filaggrin. Filaggrin is a 
crucial component of the cornified layer and helps keratin filaments aggregate 
(McGrath and Uitto 2008). Another important protein synthesised in this layer is 
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loricrin, which is a major component of the cornified layer, as set forth below (Mehrel 
et al 1990). The differentiating cells present in this layer are permeable and allow an 
influx of calcium that in turn causes the activation of transglutaminases, which are 
involved in the covalent cross-linking of the proteins produced here to form high-
molecular weight components that attach to the membrane lipids (Hitomi 2005). There 
are several transglutaminases expressed in the skin, mainly 1, 3 and 5. As previously 
mentioned, they are regulated by a rise in intracellular calcium. When this occurs, it 
causes transglutaminases to become activated, resulting in them crosslinking involucrin 
and other desmosomal proteins such as envoplakin and periplakin (Hitomi 2005). This 
results in the production of a mono-molecular layer that forms a scaffold. This scaffold 
can be utilised as a platform for the addition of other reinforcement proteins, such as 
loricin and small proline-rich proteins (SPRs), which can be cross-linked to form homo- 
and heterodimers. Loricrin constitutes around 80% of the cornified cell envelope 
(Kalinin et al 2001), which is complexed with varying amounts of small proline-rich 
proteins.  
 
During this process, other cell components and organelles are degraded. The keratin 
intermediate filaments remain, which at this stage of epidermal differentiation are 
mainly K1 and K10 (Kalinin et al 2001). These are also cross-linked to the cornified 
cell envelope, desmoplakin and envoplakin remnants and involucrin, loricrin and SPRs. 
Thus, the resultant dead cornified cell contains mostly bundled intermediate filaments 
that are covalently attached to and enclosed within the cell envelope (Kalinin et al 
2001). This results in a barrier that is durable but also flexible, and is able to provide 
mechanical and water-permeability functions necessary for the survival of the body. 
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1.1.2 The Dermis 
 
The dermis is located between the epidermis and the subcutaneous layer and is 
composed is connective tissue that adds to the overall stability of the skin. The dermis 
can be defined as two distinct layers, the papillary dermis and the reticular dermis. The 
papillary dermis is the most superficial of the two layers, and is approximately 300-
400µm deep (Sorrell and Caplan 2004). The upper section of this layer forms dermal 
projections containing components that help maintain the epidermis. The papillary 
dermis is thinner than the reticular dermis, and is composed predominantly of loose, 
poorly organised collagen fibre bundles, as well as elastic fibres. The major collagens 
found here are type I and type III. In addition to these fibrous collagens, non-fibrillar 
collagens, such as type XII and XVI are also present in the papillary dermis (Berthod et 
al 1997, Walchli et al 1994). 
 
A vascular plexus demarcates the lower limit of the papillary dermis (Sorrell and 
Caplan 2004). The reticular dermis extends from this plexus down until it reaches 
another plexus that marks the boundary between the dermis and the subcutaneous layer. 
The reticular layer is more dense than the papillary dermis, composed of thick, well-
organised collagen fibre bundles, mainly consisting of a low ratio of type III collagen to 
type I. Proteoglycans, such as decorin, are dispersed between the collagen fibres in this 
layer, whereas versican is expressed in highly quantities in the elastic fibres of the 
reticular dermis (Zimmermann et al 1994). Non-fibrillar collagens are also expressed in 
the reticular dermis, most notably, collagen type IV (Sorrell and Caplan 2004). 
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The predominant cell type present in the dermis are fibroblasts. They are involved in the 
regulation of the proliferation of keratinocytes in culture and also play roles in wound 
repair. Factors produced by fibroblasts, such as granulocyte-macrophage colony-
stimulating factor (GM-CSF), FGF-10 (KGF-2), parathyroid-hormone-related protein, 
hepatocyte growth factor/scatter factor (HGF/SF), epidermal growth factor (EGF) and 
IL-6, are all involved in modulating the activity of keratinocytes in response to various 
stimuli, such as injury (Sorrell and Caplan 2004). The papillary dermis is more 
metabolically active and contains more fibroblasts than the reticular dermis (Harper and 
Grove 1979), which one would expect since it is the closest to the epidermis and thus 
supplies the keratinocytes therein with the stimulatory or inhibitory signals that govern 
their proliferation and differentiation. 
 
1.1.3 The subcutaneous layer 
 
The subcutaneous layer is the lowermost layer of the skin. Although the subcutaneous 
layer is not technically part of the skin, connective tissue fibres from the reticular layer 
are extensively interwoven with those of the subcutaneous layer. The superficial region 
of this layer contains large arteries and veins that supply the dermis and, by diffusion, 
the epidermis with nutrients essential for the maintenance and homeostasis of the skin. 
It is predominantly composed of loose connective tissue and adipose tissue. The 
subcutaneous layer has an important role in the regulation of skin temperature as well as 
contributing to the control of body temperature. The thickness of this layer varies from 
person to person. The subcutaneous layer also plays a role in protection of the internal 
organs and skeleton through the storage of fat deposits. 
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1.1.4 The Immunology Of The Skin 
 
The skin serves as a very important component of the body’s immune system, with the 
epidermal barrier involved in innate immunity where the body defends itself against 
invading pathogens by the mobilisation of immune cells in a non-specific manner. It is 
vitally important that the immune response exhibited by the skin in response to 
pathogens is suitable. If the response is inadequate it could lead to serious infection or 
the development of tumours, whereas if it is excessive it can cause chronic 
inflammation and autoimmunity (Nestle et al 2009). There is a wealth of immune cells 
found the skin. In the epidermis, Langerhans cells, other dendritic cells and T cells are 
abundant, whereas in the dermis, innate immune cells, CD4+ T helper cells, natural 
killer T cells, macrophages, mast cells and fibroblasts are all present (Figure 1.1). 
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Figure 1.1: The Skin Contains Many Different Immune Cells. The skin is a highly 
complex structure tasked with defending the body against invading pathogens as well as 
maintaining body temperature and providing sensory information to the central nervous 
system. There are many different immune cells present in normal healthy skin, in the 
epidermis, Langerhans cell and CD8+ T cells are found. In the dermis, there are a wider 
variety of immune cells present, such as plasmacytoid dendritic cells, CD4+ TH1 cells, 
CD4+ TH17, fibroblasts, macrophages, natural killer T cells, mast cells, CD4+ TH2 and 
dermal dendritic cells. All these cells play a pivotal role in maintaining skin immune 
homeostasis. Modified from (Nestle et al 2009). 
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As previously discussed, keratinocytes are the major cell type in the epidermis. These 
cells are also capable of sensing pathogens, and help to differentiate between harmless 
organisms and harmful pathogens (Nestle et al 2009). Utilising various receptors 
expressed on their membrane, keratinocytes can recognise microbial products via 
recognition of conserved elements contained within them termed pathogen-associated 
molecular patterns (PAMPs). Toll-like receptors (TLRs) are the most well known of 
these receptors, and once activated, contribute to the TH1-type immune response via the 
secretion of type I interferons (IFNs) (Miller and Modlin 2007). In addition to TLRs, 
keratinocytes also express proteins that are the products of the nucleotide-binding 
domain, leucine-rich repeat-containing (NLR) gene family, which are capable of 
recognising PAMPs. They are able to form a complex with apoptosis associated speck-
like protein and pro-caspase 1 that is termed the inflammasome (Martinon et al 2009). 
The formation of the inflammasome leads to the activation of caspase I, which cleaves 
pro-IL1" and pro-IL18, resulting in the production of pro-inflammatory cytokines. 
Keratinocytes produced antimicrobial peptides, particularly "-defensin and 
cathelicidins, which can be increased in response to skin infection by T cell-derived 
cytokines, such as IL-17A and IL-22, which are produced by TH17 cells (Liang et al 
2006), thereby providing a link between keratinocytes and adaptive immune cells. 
Keratinocytes secrete a milieu of cytokines, IL-1, IL-6, IL-10, IL-18 and TNF, which 
lead to the activation of TH cells and dendritic cells as well as stimulating B cell 
maturation (Nestle et al 2009). Expression of various molecules on their cell surface 
allows keratinocytes to attract effector T cells and neutrophils and regulate the 
trafficking of Langerhans cell precursors. Although there are many specialised immune 
cells present in the skin, keratinocytes play a central role to the recruitment of many of 
these cells via the secretion of various cytokines and expression of molecular markers. 
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Dendritic cells constitute a large number of the immune cells that are present in the 
skin. Langerhans cells are predominantly expressed in the epidermis, particularly the 
suprabasal layers (Nestle et al 2009). Langerhans cells are the first line of defence 
against invading microbial antigens. They contain a unique cytoplasmic organelle called 
the Birbeck granule (Nestle et al 2009). Langerhans cells’ primary function is to take up 
invading antigens and process them for presentation to effector T cells. They have also 
been shown to induce differentiation of TH2 cells as well as prime and cross-prime 
naïve CD8+ T cells (Klechevsky et al 2008). Inflammatory dendritic epidermal cells 
(IDEC) are also present in the epidermis and play a role in pro-inflammatory allergic 
reactions, due to the increased expression of the high affinity Fc receptor for IgE. As 
well as epidermal dendritic cells, there are a number of dermal dendritic cells found in 
the skin. Dermal dendritic cells are capable of inducing T cell proliferation (Fukunaga 
et al 2008) and also secrete cytokines and chemokines to generate a cytokine network, 
which can be beneficial as it eradicates infectious agents but if unchecked then can 
contribute to a unnecessary inflammatory reaction (Nestle et al 2009). There are 
subtypes of dermal dendritic cells that are capable of producing either TNF or iNOS. 
Another subset of dendritic cells, termed plasmacytoid dendritic cells are rare in healthy 
skin, but are thought to play an important role in psoriasis. Finally, macrophages, which 
are also present in the dermis, are sessile (Nestle et al 2009). Under inflammatory 
conditions, these cells migrate to the lymph nodes (van Furth et al 1985) and aid in the 
eradication of invading microbes. There is a wealth of dendritic cells present in the skin 
that all contribute to the immune homeostasis of the skin. 
 
The most prevalent immune mediators present in the skin are T cells. In normal healthy 
skin, there can be as many as 2 x 1010 T cells (Clark et al 2006), which is more than is 
present in the blood. Epidermal T cells are found in the basal and suprabasal layers of 
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the epidermis, usually in close proximity with Langerhans cells. CD4+ TH cells, of 
which there are 3 main types, TH1, TH2 and TH17, are found in skin during various 
inflammatory diseases (Nestle et al 2009). The different subsets of T cells have different 
roles in inflammatory responses, with TH1 cell responses contributing to autoimmunity 
and immune-mediated pathologies, whereas TH2 cell responses are associated with 
allergic disease. TH17 has been shown to be involved in both pathways, and is essential 
for first line defence against various fungal and bacterial infections (Weaver et al 2007). 
Like the other immune cells present in the skin, T cells serve as immune sentinels with a 
role in homeostasis.  
 
1.2 Psoriasis 
 
Psoriasis is an inflammatory skin disease that affects around 1-2% of the population. It 
appears to be most common in people of Caucasian descent. The prevalence of psoriasis 
can be affected by latitude, which is presumed to be due to the fact that sunlight has a 
beneficial effect on the disease (Griffiths and Barker 2007). It can occur at any age, the 
estimated mean age of onset is 33 years of age, with 75% of cases occurring before the 
age of 46. In a subgroup of patients, psoriasis also causes arthritis (Lowes et al 2007). 
Broadly, psoriasis is comparable to other immune-mediated disorders such as Crohn’s 
disease, rheumatoid arthritis, multiple sclerosis and juvenile-onset diabetes in that it 
involves inappropriately activated effector immune function. 
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1.2.1 Clinical Features 
 
Psoriasis is a papulosquamous disease with varying morphology, distribution, severity 
and course (Langley et al 2005). Papulosquamous diseases are characterised by the 
presence of scaling papules and plaques on the surface of the skin, that are <1cm in 
diameter and >1cm in diameter respectively. The plaques observed in psoriatic patients 
are often red, scaly and raised, as shown in figure 1.2. Psoriasis develops or is worsened 
at sites of mechanical friction, which may explain why plaques are commonly observed 
on elbows, knees and the scalp. In addition, plaques adopt a symmetrical distribution, 
the reason for which is unknown. A phenomenon associated with psoriasis, termed 
Knoeber Phenomenon, is when psoriasis develops at the site of trauma (Langley et al 
2005). 
 
 
Figure 1.2: Clinical Photograph Detailing Plaque Psoriasis. The left panel shows a 
patient with psoriasis on the back, note the symmetrical distribution of plaques. The 
right panel shows a close up photograph of a psoriasis plaque, showing well 
demarcated edge and silvery scale. Modified from (Langley et al 2005). 
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There are 3 principal histological features of psoriasis, epidermal hyperplasia, dilated, 
prominent blood vessels in the dermis, and an inflammatory infiltrate of leukocytes 
(Langley et al 2005). Epidermal hyperplasia is due to the increase in proliferation rate of 
keratinocytes in the interfollicular epidermis (Lowes et al 2007). The epidermal rete 
pegs become elongated and project down into the dermis as shown in Figure 1.3. 
 
 
 
Figure 1.3: H&E Histology Of Human Skin. The left panel shows normal healthy 
human skin, whereas the right shows skin affected by psoriasis. Notice the increased 
thickness of the epidermis with elongation of the rete ridge. The arrow indicates the 
presence of inflammatory cells in the dermis. Modified from (Wagner et al 2010). 
 
The differentiation of keratinocytes is extensively altered in psoriasis; they mimic 
“regenerative maturation”, which is an alternative cell differentiation programme that is 
transiently expressed during wound healing. The hyperplastic epidermal changes 
observed are associated with the underexpression of markers of keratinocyte 
differentiation, including keratin 1 and 10 (Griffiths and Barker 2007). Involucrin is 
upregulated in psoriasis, whereas filaggrin is downregulated (Rashmi et al 2009). In 
addition, the granular layer, where terminal differentiation initiates, is vastly reduced or 
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completely absent in psoriatic skin lesions. The stratum corneum forms from 
incompletely differentiated keratinocytes that aberrantly retain a cell nucleus, a process 
termed parakeratosis (Lowes et al 2007). As a consequence, scaling and a break in the 
protective barrier occurs in the skin of psoriasis patients, due to a failure of psoriatic 
corneocytes to stack normally and secrete lipids that enables them to adhere to one 
another. Keratinocyte transglutaminase type I (TGase K) is overexpressed in psoriasis 
and is responsible for the excessive cornification observed in psoriatic plaques 
(Schroeder et al 1992). 
 
In addition and as mentioned previously, there is an increase in the vascularity of 
psoriatic lesions and this explains the redness associated with plaques. This is due to 
angiogenic factors produced by keratinocytes, such as vascular endothelial growth 
factor (VEGF), which is upregulated in psoriatic plaques (Simonetti et al 2006). 
Another hallmark of the disease is the presence of neutophils in the small foci of the 
stratum corneum, (termed Munro’s microabscesses) and there is an increase in the 
number of T cells found in lesions, interspersed between keratinocytes and in larger 
quantities in the dermis (Krueger and Bowcock 2005). As a result there is a 
mononuclear inflammatory cell infiltrate dominated by T cells, as shown in Figure 1.4. 
Neutrophils are also recruited into lesions from blood stores (Lowes et al 2007). 
Keratinocytes release pro-inflammatory cytokines and chemokines that may produce a 
chemotactic gradient for the migration of neutrophils in to the epidermis, predominantly 
IL-8, CXCL1 and S100A7/A8/A9. 
 
A major feature of psoriasis is the aberrant keratinocyte proliferation that is observed, 
resulting in psoriatic plaques. Stem cells and transit amplifying cells form the major part 
of proliferating cells in the epidermis, and are functionally altered in psoriasis. A study 
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investigating the spatial distribution of c-Jun revealed that c-Jun is expressed in the 
lower proliferation compartment of the epidermal tissue, where it is not expressed in 
normal healthy skin (Grabe and Neuber 2007, Mehic et al 2005). In addition, keratin 
expression is altered, with K6 and K16, which are markers of abnormal 
hyperproliferative conditions, being upregulated in psoriasis (Rashmi et al 2009). In 
psoriatic skin, keratinocytes take as little as 6-8 days to reach the surface from the basal 
layer, compared to the approximately 40 days that it takes in normal skin (Bergstresser 
and Taylor 1977, Roberson and Bowcock 2010). Not only are keratinocytes 
hyperproliferative, they also appear to be resistant to apoptosis, unlike normal 
keratinocytes. This may explain why there are increased numbers of keratinocytes in 
psoriatic skin, not only are they hyperproliferative but they are able to evade apoptosis 
as well. 
 
1.2.2 Pathogenesis of Psoriasis 
 
Until 1980, psoriasis was believed to be a disease of epidermal keratinocyte 
proliferation and the cutaneous inflammatory infiltrate was thought to be a secondary 
event (Griffiths and Barker 2007). It is now widely accepted that psoriasis is an immune 
mediated disorder. As mentioned previously, there is an infiltrate consisting mainly of T 
cells, both CD4+ and CD8+ and it is proposed that this precedes the epidermal 
hyperplasia observed in psoriasis. Th1 cells (CD4+), Tc1 cells (CD8+), and Th17 cells 
are all present in psoriatic lesions. There are some CD8+ T cells present that are 
specialized for homing into the epidermis via the expression of #E"7 integrin, which is 
capable of binding E-cadherin on keratinocytes. In addition, many T cells express 
CD161 and other killer receptors, which suggests a role for natural killer (NK) T cells 
(Lowes et al 2007). As previously mentioned, Th1 cells are present in psoriatic skin, 
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and in conjunction with this, levels of IFN-$, TNF-# and IL-12, which are Th1 
cytokines, are all elevated in psoriasis. The classical Th2 cytokines, IL-4, IL-5 and IL-
10 appear to protect against psoriasis, and this is further supported by the success of IL-
4 and IL-10 in clinical trials, suggesting that a shift of cytokine milieu from Th1 to Th2 
may reverse psoriasis inflammation (Mak et al 2009). By contrast, Th17 cells, that are 
also present in psoriatic skin, produce IL-17A, IL-17F, IL-22 and IL-26, which are pro-
inflammatory cytokines, activating keratinocytes and leading to hyperproliferation and 
further pro-inflammatory cytokine production. This activation and subsequent 
recruitment of other immune cells causes an amplification of the inflammatory 
response. It is becoming apparent that there are a number of different cytokine 
signalling cascades activated in psoriasis that converge together and result in a psoriatic 
phenotype. 
  
Dendritic cells also appear to be involved in the pathogenesis of psoriasis. Thus, 
epidermally located Langerhans cells, dermal dendritic cells and the so-called 
plasmacytoid dendritic cells (pDCs) are present in increased numbers in psoriatic skin 
(Griffiths and Barker 2007). pDCs produce IFN-# in response to stimulation via TLR 
signalling (Mak et al 2009), driving Th1 responses. This is consistent with the view that 
psoriasis is not only a Th17, but also Th1 mediated disorder. IFN-# produced by pDCs 
occurs early on in psoriasis development and is transient, reducing as the disease 
progresses. Langerhans cells, which are expressed in the epidermis, show impaired 
migration in response to cytokine and allergic stimuli, another key feature of early onset 
psoriasis. Finally, adhesion molecules that promote leukocyte adherence, are highly 
expressed in psoriatic skin, predominantly ICAM-1, which is expressed on epidermal 
keratinocytes and E-selectin which is expressed on dermal capillaries.  
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The cytokine interactions present in psoriasis are so-called type-1, which describes a 
relationship between cytokines, such as IL-23 or IL-12, production of IFN-$ and TNF-# 
production by type 1 T cells and downstream activation of IFN-response genes via 
STAT1 (Lowes et al 2007). In line with this, the expression of various signal 
transducers is upregulated in psoriasis, in particular STAT1, STAT3 and NF%B. IFNs 
have been described to activate STAT1 and TNF or IL-1 pathways, which are capable 
of activating the NF%B signalling cascade. In addition, IL-20 and IL-22 pathways have 
been shown to activate both STAT and NF%B pathways. This highly complex set of 
events is summarised in figure 1.4. NF%B thus has a central downstream role in many 
cellular processes in psoriasis, with roles in stress responses and keratinocyte 
proliferation and differentiation (Roberson and Bowcock 2010) 
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Figure 1.4: Potential Cytokine Signalling Pathways In Psoriasis. The above diagram 
demonstrates the possible interactions that occur in psoriatic skin, with the activation of 
pDCs occurring via environmental factors, heat shock proteins, TLR agonists, cytokines 
or infection. However this can also occur due to direct interaction with T cells. As a 
result, various cytokine and chemokine signalling cascades are triggered resulting in 
the activation of various response genes and elements and subsequent inflammation. 
(Modified from (Lowes et al 2007). 
 
1.2.3 Genetic Basis of Psoriasis 
 
Recent advances have highlighted genetic association of genes with psoriasis. Psoriasis 
is a polygenetic condition. Twin and family studies have revealed a strong genetic 
component for psoriasis, particularly in those who develop the disease before the age of 
40. Approximately 30% of individuals with psoriasis have an affected first degree 
relative (Griffiths and Barker 2007). In line with this, if both parents and a sibling suffer 
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from psoriasis, a further child has a 50% chance of developing psoriasis. However that 
risk reduces considerably if only one sibling is affected. So-called genome wide 
association scans (GWAS) have been instrumental in discovering new gene loci that 
may increase an individuals susceptibility to psoriasis and have identified new candidate 
genes that are consistent with the pathological changes observed. 
  
Due to the strong immune system activation in psoriasis, early genetic studies targeted 
genes and loci that were known to encode for components of the immune system. MHC 
class II molecules were investigated first, as it was hypothesised that immune cells in 
psoriasis were reacting to an unidentified antigen (Roberson and Bowcock 2010). These 
studies revealed an association between psoriasis and the expression of human 
leukocyte antigen (HLA) class 1 alleles, with the strongest association being HLA-Cw6 
(Roberson and Bowcock 2010, Tiilikainen et al 1980). The frequency of HLA-Cw6 was 
46% in psoriasis compared to 7.4% in controls. However, despite the high incidence of 
this allele in psoriasis cases, the presence of this risk allele is not sufficient for disease 
development, with the penetrance estimated to be only 10%. Later GWAS studies 
revealed SNPs in genes present in the MHC class I, which is physically close to the 
HLAC gene (Liu et al 2008). SNPs that have been found to be associated with psoriasis 
are correlated with the gene encoding for HLA-Cw6. Located close to the HLA-Cw6 
gene is another gene implicated in psoriasis, corneodesmosin. Corneodesmosin has also 
shown to be associated with psoriasis, with two different alleles of the gene found on 
known psoriasis-associated haplotypes that also harbour HLA-Cw6 (Nair et al 2000). 
However, this indicates that corneodesmosin is no more responsible for the psoriasis 
phenotype than HLA-Cw6. 
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GWAS studies also confirmed association of IL-12B and IL-12R, both of which had 
been previously discovered via genetic linkage studies. This study also identified 
several new candidates, including IL-23A, IL4/IL13, TNFAIP3 (TNF# induced protein 
3) and TNIP1 (TNFAIP3 interacting protein) (Elder et al 2010, Nair et al 2008, Nair et 
al 2009). In addition, there is also a strong association between psoriasis and the region 
of the late cornified envelope (LCE) genes. Under normal skin conditions, LCE1 and 
LCE2 are expressed in the skin and are incorporated into the cornified envelope very 
late in its development (Roberson and Bowcock 2010). However, following tape 
stripping, which disrupts the cornified layer and leads to epidermal damage, in psoriatic 
skin, LCE3 expression, is induced (de Cid et al 2009, Elder et al 2010, Roberson and 
Bowcock 2010). Inappropriate expression of LCE genes could therefore lead to an 
inappropriate repair response following barrier disruption, due to the repair being 
insufficiently supported by other LCE genes (de Cid et al 2009, Roberson and Bowcock 
2010). 
 
Further associated genes include IL12B and IL23R (Nair et al 2008). The IL12B gene 
encodes the p40 subunit, which is common to both IL12 and IL23, which are both 
implicated in the pathogenesis of psoriasis. The IL23R gene on the other hand encodes 
the subunit for the IL23 receptor, which has also been described to play a role in 
psoriasis. In a subsequent study several other candidate genes were identified, 
particularly several involved with NF%B signalling as well as IL23 signalling (Nair et al 
2009) including IL23A, which encodes the p19 subunit of IL23. IL23 signalling is 
necessary for the activation and expansion of Th17 cells, an important feature in the 
pathogenesis of psoriasis. 
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Furthermore, the "-defensin cluster on chromosome 8p21 exhibits increased copy 
numbers in psoriasis patients (Hollox et al 2008, Roberson and Bowcock 2010). "-
defensins are small, antibiotic peptides that play a role in the non-specific host defence 
system. "-defensins are secreted in psoriatic skin by keratinocytes due to the cytokine 
environment present, a process that can also be enhanced in response to NF%B 
signalling (Roberson and Bowcock 2010), again suggesting involvement of NF%B in 
psoriasis pathology. The expression of "-defensin will attract various immune cells, 
specifically T cells, dendritic cells and neutrophils, all of which are implicated in 
disease pathogenesis.  
 
Finally, Nair and colleagues identified genes implicated in the modulation of the 
immune response including IL4 and IL13, which are involved in the humoral response 
mediated by Th2 cells (Nair et al 2009). Possible dysregulation of these genes may 
result in a shift from a Th2 response to a Th1 response, thus explaining the marked 
expansion of Th17 cells observed in psoriatic skin.  
 
Even though GWAS and genetic linkage analysis have elucidated several major 
signalling pathways involved in psoriasis pathology, it must be stressed that aside from 
the risk locus in the HLA-C region, genetic effects of all other risk loci are small with 
effective odds ratios below 1.5, which means that the presence or absence of any one of 
these risk genes by itself has only a minor effect on the risk of having psoriasis. 
Importantly, several signalling pathways central to disease pathology do not show any 
genetic association. Thus, molecular players such as IL-1, STAT3, PPAR! or VEGF 
have never been demonstrated or successfully replicated (in the case of VEGF). This 
could be due in part to these molecules signalling downstream of gene products shown 
to be risk factors.  
 
 
23 
1.2.4 Therapeutic Approaches 
 
A number of different therapeutic approaches are available for the treatment of 
psoriasis. Traditional topical therapies, including phototherapy, such as corticosteroids 
and vitamin D analogues and conventional systemic therapies have been employed for 
decades, whereas newer biological treatments, targeting specific cytokines, are 
becoming more widely available.  
 
Topical Therapies 
 
Topical corticosteroids have been a common treatment for psoriasis for decades (Bagel 
2009, Mitra and Wu 2010). They are useful for localised plaques, whereas generalised 
plaques are better treated with phototherapy or a systemic therapy. The efficacy of 
topical corticosteroids may be attributed to multiple mechanisms of actions that they 
display, including anti-inflammatory, immunosuppressive and anti-proliferative effects 
(Mitra and Wu 2010). Although effective, topical and easy to use corticosteroids do 
carry a risk of developing adverse effects (Horn et al 2010). A number of 
corticosteroids, ranging from high to low potency are available commercially for 
treatment, including clobetasol propionate, betamethasone dipropionate and 
triamicinolone. Other topicals include analogues of vitamin D such as calcipotriol, 
tacalcitol and maxacalcitol. They have all been demonstrated in vitro to have an effect 
on corneocyte proliferation and differentiation (Mitra and Wu 2010). Calcipotriol, a 
synthetic analogue of vitamin D, has been shown to have anti-proliferative effects at 
pharmacologically relevant concentrations, as well as pro-differentiation effects on 
keratinocytes (Lehmann 2009). Beyond vitamin D analogues, dithranol, coal tar and 
emollients act broadly and with the exception of emollients, which have been shown to 
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provide a barrier where it has been lost, have poorly defined specificity.  
 
Systemic Therapies 
 
Systemic therapies for psoriasis, particularly generalised psoriasis, have proved quite 
effective in treatment. Methotrexate, initially used in the treatment of cancer, was first 
observed to have a therapeutic benefit in cancer patients suffering from psoriasis 
(Warren and Griffiths 2008). Methotrexate raises the intracellular levels of adenosine, 
which may influence leukotriene production, T cells and adhesion molecule expression 
(Warren and Griffiths 2008) and is also anti-proliferative. 
  
Retinoids are also used in the systemic treatment of psoriasis. Acitretin, a retinoid, is 
able to activate all subtypes of retinoic acid receptors and as such directly affects 
keratinocytes via returning their proliferation and differentiation status towards normal 
levels. Retinoids have also been described to inhibit VEGF, although this is an indirect 
effect mediated by activator protein 1 (AP1) (Diaz et al 2000). Finally, retinoids have 
been shown to modulate T cell responses and inhibit chemotactic responses and 
activation of polymorphonuclear leukocytes, such as neutrophils, eosinophils and 
basophils (Warren and Griffiths 2008). 
  
Cyclosporine, a calcineurin inhibitor, is often used in the treatment of psoriasis.  It binds 
ciclophilin (Ho et al 1996) and the resultant cyclosporine-ciclophilin complex inhibits 
the activity of calcineurin phosphatase, which is responsible for the dephosphorylation 
of nuclear activated T cells. This dephosphorylation stimulates the translocation of 
nuclear factor of activated T cells into the nucleus, thus activating T cells and 
stimulating the release of cytokines, such as IL2 and IFN$.  
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So-called “biological” agents (monoclonal antibodies) are increasingly used in the 
treatment of refractory psoriasis. Development of biologics has arisen from our 
increased understanding of the involvement of the immune system in psoriasis (Rich 
and Bello-Quintero 2004). Biologics that have proved most successful in the treatment 
of psoriasis are those that target TNF signalling. Examples of anti-TNF biologicals are 
infliximab and etanercept (Krueger and Bowcock 2005).  
 
Phototherapy is an important systemic therapy in the treatment of psoriasis. It has long 
been known that sunlight is beneficial to those with psoriasis and is often used in 
conjunction with other topical or systemic therapies (Lebwohl and Ali 2001). PUVA, 
which involves ingestion of 8-methoxypsoralen (8-MOP) followed by exposure of the 
skin with UVA has proven to be very effective, however its use is declining due to the 
association with the development of cutaneous malignancies (Lebwohl and Ali 2001). 
To lower the risk of malignancies developing, PUVA is now used in association with 
other treatments for psoriasis and in some cases, is alternated with other therapies. 
 
1.3 Animal Models of Psoriasis 
 
Numerous animal models targeting various pathological mechanisms and exhibiting 
certain aspects of psoriasis have been generated. For example, animal models that 
disrupt various components of the immune system have been developed to examine 
their role in psoriasis disease development.  For example, the I%B subunit IKKB, that 
has a role in the negative regulation of NF%B signalling, has been specifically deleted in 
the epidermis, resulting in a severe inflammatory skin disease, dependent on the dermal 
expression of TNF# (Pasparakis et al 2002). These mice show altered differentiation 
and thickening of the epidermis, but also several other characteristics that are not 
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representative of psoriasis, such as keratinocyte apoptosis and T cell-independent 
inflammation. Deletion of IKKA, another catalytic subunit of I%B, results in epidermal 
abnormalities without inflammation, therefore is not representative of psoriasis 
(Gudjonsson et al 2007). Despite replicating some aspects of psoriasis, there are 
characteristics of this model that do not appear in psoriasis, thus making this model 
unsuitable for studying the pathology of psoriasis. 
 
Transgenic mouse models that mimic the overexpression of cytokines thought to be 
crucial in psoriasis also fail to replicate many aspects of the disease. Thus, 
overexpression of TNF# targeted to the epidermis caused retardation of hair growth, 
inhibition of adipose production, signs of fibrosis and immune infiltration in the dermis 
with subsequent necrosis and cachexia (Cheng et al 1992). While this data suggests that 
TNF# expression by keratinocytes plays an important role in modulating the immune 
response it doesn’t clarify how TNF# is involved in psoriasis. Another important 
cytokine in psoriasis, IFN$, induces keratinocyte proliferation when injected into 
normal skin (Barker et al 1993). Mice that express IFN$ in the suprabasal layer of the 
epidermis display reddened skin, growth retardation, hair loss and flaky skin lesions. In 
addition, keratinocyte proliferation was increased and there was marked epidermal 
thickening, parakeratosis and an inflammatory infiltrate was also observed (Carroll et al 
1997). However these mice are more representative of atopic dermatitis than psoriasis. 
Similarly, mice that constitutively express the p40 subunit of IL12 and IL23 in basal 
keratinocytes develop an eczematous phenotype, which can be replicated by 
subcutaneous injections of IL-12 (Kopp et al 2001). This is disappointing given the 
body of evidence implicating IL-23/IL-12 signalling in the pathogenesis of psoriasis. 
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Due to the polygenic nature of psoriasis, the development of an animal model that 
replicates all aspects of the disease is unlikely. In light of these limitations, xenograft 
models, where the skin of psoriasis patients is transplanted onto immunosuppressive 
mice have been generated. Three different strains of immunocompromised mice have 
been utilised, nude mice, severe combined immunodeficiency (SCID) mice and 
AGR129 mice. The most promising of the three strains is the AGR129 mouse. AGR129 
mice are deficient in type I and type II IFN receptors and also lack the recombinase 
activating gene-2 gene (Boyman et al 2004). In addition, these mice also lack T- and B-
cells and have immature NK cells that display impaired cytotoxicity activity in vitro and 
in vivo. Boyman et al showed that transplantation of non-involved skin from a psoriatic 
patient spontaneously develops into a psoriatic skin lesion (Boyman et al 2004). 
Following the transplantation of the skin onto the AGR129 mouse, T cells present in the 
graft undergo local proliferation and activation, a process that is inhibited by treatment 
of the grafts with anti-CD3 antibody (Boyman et al 2004, Gudjonsson et al 2007). The 
expansion of CD8+ T cells is particularly important for the development of the lesion in 
the graft. 
 
In SCID mice, injecting superantigen-stimulated blood-derived immunocytes under the 
transplanted skin was able to induce the development of a psoriatic lesion (Wrone-
Smith and Nickoloff 1996). SCID and AGR129 xenograft models have provided 
evidence supporting the belief that psoriasis is a T-cell-mediated disease. Despite their 
ability to mimic psoriasis, all xenograft models are limited by their low throughput 
nature, the need to obtain human skin for each mouse, and the immune-deficient 
background for their generation, which inherently deviates from the highly immuno-
active context of psoriasis lesions. None of these models have successfully been used in 
a high throughput fashion for testing of novel treatments to date. Nonetheless, these 
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xenograft models are currently the best available for the replication of the human 
disease. 
 
Some of the most interesting models that have been developed target growth factors and 
signal-transducing molecules, such as STAT3 and VEGF. STAT3 is known to have a 
role in cell proliferation, survival and cell migration, making it an interesting candidate 
for psoriasis disease progression. STAT3 has also been shown to play a role in wound 
healing (Sano et al 1999) and is activated in psoriasis (Sano et al 2005). To this end, 
Sano and colleagues developed a constitutively active STAT3-expressing mouse model 
that develops lesions that are similar to psoriasis either spontaneously or in response to 
tape stripping (Sano et al 2005). It mimics many of the key histological features 
displayed in psoriasis, such as acanthosis, loss of the granular layer and parakeratosis. 
In addition, dilated blood vessels and a leukocyte infiltrate were also observed. This 
infiltrate is composed mainly of CD4+ T cells in the upper dermis and epidermis, with 
few CD8+ T cells localised in the epidermis. Interestingly, grafts from these mice 
transplanted onto immunodeficient mice showed no phenotype, however following 
injections of T cells from the STAT3 mutants under the graft, a psoriatic phenotype was 
observed. Therefore development of lesions in this model is clearly dependent on T cell 
activation (Gudjonsson et al 2007, Sano et al 2005). A potent activator of STAT3, IL-
20, has been expressed by targeting its expression to the basal layer. This targeted 
expression results in abnormal keratinocyte differentiation with expression of the 
regenerative maturation marker keratin 6 (K6) (Blumberg et al 2001). A thickened 
hyperkeratotic epidermis and compact stratum corneum were also observed. Supporting 
the role of STAT3 in psoriasis, a mouse model in which VEGF was specifically 
expressed in the basal layer was established. VEGF signals via STAT3 and is able to 
induce proliferation of human keratinocytes (Gudjonsson et al 2007). Mice that 
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overexpress VEGF in the basal layer develop a psoriasis like phenotype and also display 
a similar response to injury as seen in the Koebner phenomenon (Xia et al 2003). These 
mice showed hyperplastic dermal blood vessels, epidermal thickening with dysregulated 
keratinocyte differentiation and characteristic inflammatory infiltrates. Furthermore, the 
phenotype is reversed by treating mice with a VEGF antagonist (Xia et al 2003).  
 
Although many of these models do not exhibit a “pure” psoriasis phenotype, they do 
provide insight into the possible roles of various dysregulated components of disease 
pathogenesis. However, many of the models discussed here have not been tested to 
assess current psoriasis treatment efficacy, a parameter that could, if efficacy were 
shown, support the legitimacy of the model as a representation of human psoriasis. 
Thus, there remains a need for a good model that replicates many, if not all, aspects of 
the disease. 
 
1.4 PPAR! 
 
1.4.1 Family of Peroxisome Proliferator Activated Receptors (PPARs) 
 
Peroxisome proliferator activated receptors (PPAR) are ligand activated transcription 
factors that belong to the nuclear hormone superfamily. There are 3 different isotypes of 
PPARs, PPAR# (NRIC1), PPAR"/! (NRIC2, referred to as PPAR!) and PPAR$ 
(NRCI3) (Michalik et al 2006). PPAR$ exists as two splice variants, PPAR$1 and 
PPAR$2, which arose during evolution by gene duplication that gave rise to PPAR$. 
For the PPARs to be able to regulate transcription, unlike other nuclear hormone 
receptors, which form homodimers following activation, PPARs require 
heterodimerisation with the retinoid X receptor (RXR), a member of the same 
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superfamily of receptors (Michalik et al 2006). These PPAR/RXR heterodimers can 
form in the absence of a ligand and, when activated are able to mediate transcription by 
binding to a specific DNA sequence element, the peroxisome proliferator response 
element (PPRE) on the target gene (Michalik et al 2006). The PPRE is composed of 2 
half-sites, which occur as a direct repetition (DR1 repeats) of the consensus sequence 
AGGTCA, with a single nucleotide spacing in between the repeats. These PPRE 
sequences are present in one or multiple copies in the promoter region of target genes. 
The PPAR/RXR heterodimer bind to the 5’ and 3’ half-sites of PPRE respectively, with 
the 5’ flanking region determining the selectivity of binding of different PPAR isotypes.  
 
1.4.2 Structure of PPARs 
 
All 3 PPAR isotypes are similar in structure, differing only in the percentage of 
homology between the DNA binding domain and ligand-binding domain. PPARs have 
an N terminal domain, termed the A/B domain, which contains a ligand-independent 
transcriptional function and which in PPAR# and PPAR$ can be regulated by MAPK 
phosphorylation (Hihi et al 2002). The C domain forms the DNA binding domain, 
which is characterised by 2 zinc-finger-like motifs, similar to those that have been 
described for steroid receptors. The E/F domain contains the ligand-binding domain, 
that contains a ligand-dependent transactivation function, AF-2, which is able to interact 
with transcriptional co-activators, regulating the transcriptional control of the 
PPAR/RXR heterodimer (Michalik et al 2006). The ligand-binding domain is depicted 
in the 3D crystal structure filled with white to mark the location on each PPAR isoform 
(figure 1.5).  
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Figure 1.5: Structure Of PPARs. A shows a schematic representation of PPAR, 
depicting the functional domains, which are described in the text. B shows the 3D 
structure of the ligand-binding domain of each of the PPARs. Modified from (Hihi et al 
2002) 
 
Binding of ligands to the ligand-binding site induces a conformational change that 
favours the dissociation of co-repressors and stimulates the heterodimerisation with 
RXR and the recruitment of co-activators, which in turn recruits RNA polymerase and 
initiates remodelling of histones near regions of DNA containing DR1 motifs, thereby 
increasing the transcription of target genes (Peters and Gonzalez 2009).  
 
1.4.3 PPAR! Function 
 
Unlike PPAR# and PPAR$, which are only expressed in specific tissues, PPAR! 
expression is found in virtually all tissues, in varying levels (Peters and Gonzalez 2009). 
Expression levels appear to be dependent on extent of cell proliferation and 
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differentiation that occurs in a particular tissue (Michalik et al 2006), with expression 
highest in skin, gut, placenta, skeletal muscle, adipose tissue and brain. PPAR! has a 
role in cell proliferation, cell differentiation, fatty acid catabolism and development. 
The development of specific PPAR! synthetic agonists such as GW501516 (Sznaidman 
et al 2003) has contributed towards elucidating its role in lipid metabolism. Dosing of 
insulin-resistant obese rhesus monkeys with the specific PPAR! agonist GW501516 for 
4 weeks resulted in the normalising of fasting glucose and insulin levels, increased 
high-density lipoprotein cholesterol and a reduction in low-density lipoprotein 
cholesterol (Luquet et al 2004, Oliver et al 2001). Increased insulin sensitivity and a 
decrease in adiposity in obese mice when treated with the same compound, confirms 
that PPAR! plays a role in fatty acid metabolism. These data support the possible 
development of PPAR! as a target for anti-obesity and type 2 diabetes treatments. In 
addition to its role in fatty acid catabolism, PPAR! has been shown to play a role in 
lipid metabolism, particularly in skeletal muscle. This fits with PPAR! being the 
predominant isoform expressed in skeletal muscle (Holst et al 2003).  
 
Further to the actions of PPAR! on fatty acid catabolism and lipid metabolism, there 
has been some debate about its role in proliferation, particularly in keratinocytes, where 
it is highly expressed. The actions of PPAR! on proliferation appear to be dependent on 
the cellular context in which it is expressed (Romanowska et al 2008). Exacerbation of 
hyperplasia by phorbol ester in PPAR!-deficient mice suggests an inhibitory role in 
keratinocyte proliferation (Peters et al 2000). Kim et al also reports inhibition of 
keratinocyte proliferation by PPAR! (Kim et al 2006), with evidence from the null 
PPAR! transgenic mouse. Additionally, in a subsequent study by members of the same 
group, inhibition of proliferation in N-TERT cells, an immortalized keratinocyte cell 
line, was also shown (Burdick et al 2007).  In contrast to this data, Romanowska and 
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colleagues demonstrated that PPAR! enhances proliferation in primary human 
keratinocytes following activation with a selective ligand (Romanowska et al 2008). 
Critics argue that the concentrations of the specific agonists used results in activation of 
the two other PPAR isoforms, which have known stimulatory effects on proliferation 
(Peters and Gonzalez 2009). The precise role of PPAR! in keratinocyte proliferation is 
currently still debated. 
 
1.4.4 The Role of PPAR! in Psoriasis 
 
PPAR! is highly expressed in lesional skin of psoriatic patients. There is strong 
evidence to suggest a protective anti-apoptotic role of PPAR! in wound healing. In a 
study by Di Poi and colleagues, keratinocytes from PPAR!-null mice were more 
sensitive to growth factor withdrawal and anoikis (suspension-induced apoptosis) than 
+/+ PPAR! primary keratinocytes (Di-Poi et al 2003). In agreement with these results, 
when HaCaT cells are stimulated with a PPAR! agonist, L-165041, they are more 
resistant to apoptosis induced by growth factor withdrawal or anoikis. The expression of 
PPAR! is also increased following a wound, particularly at the wound edge (Sertznig et 
al 2008). These authors showed that this occurs in response to inflammatory cytokines, 
such as TNF# and IFN$ via an AP1-dependent stress response pathway, which is 
activated during wound healing. It is presumed that PPAR! expression at the wound 
edge would promote keratinocyte survival through this anti-apoptotic function, 
facilitating wound closure. 
  
As psoriasis has been described as an exaggerated wound response, it is not surprising 
that PPAR! is overexpressed in psoriatic lesions (al Yacoub et al 2008, Westergaard et 
al 2003). Expression arrays and immunohistochemical data from lesional psoriatic skin 
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confirmed that PPAR! is overexpressed in psoriasis (Romanowska et al 2008, 
Westergaard et al 2003). In addition, PPAR! was shown to interact with NF%B 
signalling, which was implicated in the pathogenesis of psoriasis (Westergaard et al 
2003).  In contrast to this, PPAR! has been described to be capable of inhibiting NF%B 
nuclear translocation induced in response to inflammatory cytokines, thus allowing 
PPAR! to exert anti-inflammatory effects (Barroso et al 2011, Peters and Gonzalez 
2009). In the study conducted by Romanowska and colleagues, it was shown that 
PPAR! induces Heparin-Binding EGF-Like Growth Factor (HB-EGF) (Romanowska et 
al 2008). HB-EGF is of interest due to being upregulated in psoriasis and has been 
shown to induce epidermal hyperplasia, a key hallmark of psoriatic disease. This 
suggests that activation of PPAR! and subsequent activation of HB-EGF contribute to 
the hyperproliferative phenotype observed in the disease. In a different study by the 
same group, PPAR! was shown to be expressed in T cells from peripheral blood and T 
cells isolated from psoriatic tissue (al Yacoub et al 2008). PPAR! was shown to 
contribute to T cell proliferation and evasion of apoptosis, suggesting a role in the 
sustainment of T cell populations in psoriasis. The authors postulate that PPAR! is a 
type I IFN target and is responsible for mediating the observed pro-survival effects (al 
Yacoub et al 2008). Given these data, it could be that PPAR! is overexpressed in 
psoriasis, and may contribute to the maintenance of the disease via induction of HB-
EGF and its anti-apoptotic effects exerted in T cell populations. It is therefore of interest 
to investigate whether overexpression or a constitutively active form of PPAR! in vivo 
may yield a hyperproliferative phenotype similar to psoriasis. 
 
To date, there is little data to support an interaction between PPAR! and STAT3. 
However, PPAR! is capable of activating a variety of tyrosine kinases, such as TGF-# 
and HB-EGF (Romanowska et al 2008), which are instrumental in the activation of 
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STAT3. It is possible that either of these two kinases, which are upregulated in 
psoriasis, could contribute to the activation of STAT3. On the histological level of 
psoriasis, it appears that STAT3 and PPAR! have the same localisation in the epidermis 
(Sano et al 2005, Westergaard et al 2003). This would suggest that there is some form 
of interaction between these two molecules, albeit indirectly. In addition, it was recently 
shown that PPAR! is capable of binding to a STAT3 response element and enhancing 
STAT3 activity (Wu et al 2010). The limited data available support the hypothesis that 
PPAR! and STAT3 interact; therefore one can assume that since both are overexpressed 
in psoriasis, they both may contribute to disease progression and sustainment. 
 
1.5 STAT3 
 
1.5.1 STAT Family of Transcription Factors 
 
Signal Transducers and Activators of Transcription (STAT) are a family of signal 
transducers involved in the regulation of gene transcription and mediating the effects of 
cytokine signalling. There are 7 family members described to date, STAT1, 2, 3, 4, 5a, 
5b and 6. STATs were discovered while investigating the downstream regulation of IFN 
signalling (Horvath 2000). These different family members are highly conserved and 
have crucial roles in the regulation of cellular functions in response to extracellular 
cytokine and growth factor signals. All STATs signal in roughly the same manner, 
following activation of a receptor with intrinsic tyrosine kinase activity, STATs bind to 
the phosphorylated tyrosine residues via a src homology 2 (SH2) phosphotyrosine-
binding domain. They are then phosphorylated at either tyrosine or serine residues and 
this allows them to form homodimers and subsequent translocation to the nucleus to 
regulate gene transcription (Horvath 2000). However, some isoforms have the ability to 
 
 
36 
form heterodimers with other members of the STAT family, for example STAT2 is able 
to form a heterodimer with STAT1, which functions downstream of IFN#, STAT1 and 
STAT3 downstream of IL6 and STAT5a and STAT5b downstream of growth factors, 
such as EGF. The majority of the STAT homodimers bind and recognise variants of 
GAS-like DNA elements TTN5–6AA, showing preference for specific sequence 
variations of the internal nucleotides of the inverted repeat (Horvath 2000). 
 
1.5.2 STAT Structure 
 
The structure of STATs is virtually the same in all isoforms, differing only in the 
transcriptional activation domain (TAD) (figure 1.6). The N domain, located at the N-
terminus of STATs has proven important for stablising interactions between dimers 
bound to promoters (John et al 1999). The coiled-coil region forms part of the core 
fragment of the STATs, its exposed surfaces present many binding sites for protein 
interactions (Horvath 2000). The coiled-coil region is linked to the DNA-binding 
domain, which binds specific sequences in the promoters of target genes. The linker 
domain composed primarily of #-helices separates the DNA-binding domain from the 
phosphotyrosine-binding SH2 domain and has also been implicated in transcription. 
The SH2 domain is involved in the binding to phosphorylated tyrosine residues on the 
activated receptors. Finally the tyrosine residue is followed by amino acids that are C-
terminally located that form the transcriptional activation domain (TAD). TAD is 
essential for STAT protein functions (Horvath 2000). 
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Figure 1.6: Schematic Showing General STAT Structure. ND represent the N-domain 
involved in dimer interactions (yellow), Coil coil domain is responsible for protein-
protein interactions (green), DNA is the DNA binding domain (red), LD is the linker 
domain involved in transcription (orange), SH2 is the SH2 domain involved in receptor 
binding and dimerisation (blue). All STATs have a tyrosine residue (Y) that is 
phosphorylated upon receptor binding causing them to become activated, many of the 
STATs also have serine residue in their transcriptional activation domain (purple). 
Modified from (Horvath 2000). 
 
1.5.3 STAT3 Function 
  
STAT3 is implicated in many cellular processes. Knockout of STAT3 results in 
embryonic lethality, pointing towards a role for STAT3 in development, however the 
mechanism for the activation of STAT3 in this particular process is still unclear (Takeda 
and Akira 2000). T-cells deficient in STAT3 show impaired IL6-induced cell 
proliferation, due to a lack of IL-mediated prevention of apoptosis of these cells 
(Takeda et al 1998). This suggests that STAT3-mediated signalling is responsible for 
the anti-apoptotic signal and leads to enhanced T cell proliferation. Mice with the 
deletion of STAT3 in these cells are more susceptible to endotoxin shock, with the 
serum concentration of inflammatory cytokines being increased (Takeda et al 1999). IL-
10, which normally has an inhibitory effect on the production of cytokines by 
macrophages and neutrophils, no longer demonstrates an effect in STAT3 deficient cells 
(Takeda et al 1999). In addition, these mice show an elevated Th1 response and develop 
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chronic enterocolitis. STAT3 is evidently involved in the mediation of cytokine 
production by macrophages and neutrophils, which appears to be dependent on IL10. 
Like the STAT5 isoforms, STAT3 also plays a role in mammary gland development 
(Chapman et al 1999).  
 
1.5.3 The Role of STAT3 in Psoriasis 
 
Several in vitro and in vivo studies support the role of STAT3 in psoriasis (Sano et al 
1999, Sano et al 2005). STAT3 has been strongly implicated in wound healing. Mice 
where STAT3 is specifically deleted from the epidermis, have retarded wound healing 
(Sano et al 1999). However, there is no difference in the dermal responses to wounds 
such as granulation, inflammation and the formation of new blood vessels in these 
STAT3 deficient mice. This directly suggests that STAT3 is primarily involved in 
epidermal regeneration and not in the development of dermal components. 
  
In addition to the strong evidence suggesting a role for STAT3 in keratinocyte biology, 
immunohistochemical analysis of psoriatic skin revealed a strong upregulation of 
STAT3 throughout the epidermis (Sano et al 2005). In the same study, Sano and 
colleagues demonstrated that keratinocyte specific overexpression of STAT3 results in a 
mouse model that develops psoriatic-like lesions, as described in section 1.4. Perhaps 
the strongest evidence for a role of STAT3 in psoriasis is the observation that 
application of a JAK2 inhibitor directly to the skin effectively heals psoriasis plaques in 
humans. Thus, Duffin and colleagues recently described the use of a JAK1/JAK2 small 
molecule inhibitor, INCB018424, which was tested in two clinical trials. This inhibitor 
was able to inhibit acanthosis and production of IL-22 induced by intra-dermal IL-23 in 
the murine model and in patients reduced transcriptional changes consistent with 
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decreases in Th1 and Th17 lymphocyte activation, decreased epidermal hyperplasia and 
dendritic cell activation (Duffin et al 2010). In addition, following a second double 
blind clinical trial, total lesion score of patients revealed a 2-fold decrease over vehicle 
control at day 84 (Duffin et al 2010). These data support a role for STAT3 signal 
transduction following phosphorylation by JAK in psoriasis disease progression. 
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1.6 Aim 
 
Based on the data outlined above, we sought to develop a transgenic mouse model that 
overexpressed PPAR!. This thesis details the characterisation and development of a 
model overexpressing PPAR! under the control of the CYP1A1 enhancer. To address 
the effectiveness of this model, the following were examined, 1) any phenotypic 
changes that occur following induction of the transgene with a specific PPAR! ligand 2) 
the localisation of PPAR! in induced and non-induced PPAR! transgenic mice, 3) 
whether there is any immune system activation in induced mice, similar to that of the 
human disease. In addition, STAT3 is highly overexpressed in psoriasis, as discussed 
previously. To investigate the contribution of STAT3 to the development of psoriasis-
like disease in PPAR! transgenic mice, the following were examined, 1) to investigate 
the expression and activation levels of STAT3 in a psoriasis-like in the vivo model, 2) 
to ascertain the effect of STAT3 inhibition on disease development in the same model 
and finally 3) to determine the effects of STAT3 on interferon response genes deemed 
important in psoriasis pathogenesis. 
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2. Materials And Methods 
 
2.1 Chemicals, Reagents And Buffers 
 
All general chemicals were of molecular biology grade and obtained from Sigma-
Aldrich (Gillingham, Dorset, UK), VWR International (Poole, Dorset, UK), Fisher 
Scientific (Loughborough, Leicestershire, UK) unless otherwise stated. 
 
2.2 Ethics Statement 
 
All work involving animals was approved by the Tayside Ethics Committee. Storage 
and use of all tissues included in the work presented here was approved by the Tayside 
Committee on Medical Research Ethics B (REC ref. Nr. 07/S1402/90). 
 
2.3 Home Office Licence 
 
In order to carry out experiments involving animals, a personal licence from the Home 
Office must be obtained. This was awarded in June 2009 following training and a 
written exam granting permission to the holder to carry out regulated procedures on 
living animals. This licence does not authorize the licensee to perform any of the 
procedures specified in it unless they are carried out in the course of a project for which 
there is a project licence in force under the Animals (Scientific Procedures) Act 1986. 
The project licence number used for this work is 60/3800 and the personal licence 
number used is PIL 60/12167. 
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2.4 PPAR! Immunohistochemistry – Human Skin 
 
Human skin biopsies embedded in paraffin were obtained from Tayside Tissue Bank. 
Prior to biopsy, patients gave written consent to storage and analysis of biopsy samples. 
Paraffin sections of skin were prepared by Tayside Tissue Bank. Following preparation 
of sections, they were deparaffinised by heating for 1 hour at 60°C then subjected to a 
series of alcohol washes in the following order, 
 
 Histoclear – 5 minutes 
 Histoclear – 5 minutes 
 Absolute Alcohol (100% IMS) – 3 minutes 
 Absolute Alcohol (100% IMS) – 3 minutes 
 Methylated Alcohol (95% IMS) – 3 minutes 
 
Following deparaffinisation, sections were subjected to antigen retrieval to unmask 
antigens that may have become masked during tissue fixation. To achieve this, sections 
were boiled in 10mM citric acid, pH=6.0 for 10 minutes. To remove residual citric acid, 
sections were washed with dH2O for a total of 3 times. Sections were incubated with 
hydrogen peroxide (3%) for 10 minutes to reduce endogenous peroxidases. Sections 
were washed in between incubation steps with TBST. Using VECTASTAIN® 
Universal Elite® ABC Kit (Vector Labs, Cat.no.: PK-6200), sections were incubated 
with normal blocking serum (5ml TBST + 1 drop Normal Blocking Serum Stock) for 20 
minutes. Excess serum was blotted from each section before proceeding with incubation 
with primary antibody against PPAR!. Primary antibody was diluted in normal 
blocking serum, 1:100 and applied to sections, which were then incubated overnight at 
4°C. 
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Antibody Manufacturer 
Monoclonal Mouse Anti-human 
PPAR!/NR1C2, Clone: K9436 
R&D Systems, Cat.no.: PP-K9436-00 
 
Table 1: Antibodies Used In PPAR! Immunohistochemistry. The same antibody was 
used for both human and mouse PPAR! immunohistochemistry. 
 
Following primary antibody incubation, sections were incubated with diluted 
biotinylated secondary antibody (5ml TBST + 2 drops Normal Blocking Serum Stock + 
2 drops of Biotinylated Antibody Stock), for 30 minutes at room temperature followed 
by a 30 minute incubation with VECTASTAIN® Elite® ABC Reagent (5ml TBST + 2 
drops Reagent A + 2 drops Reagent B). To visualise positive staining, a peroxidase 
substrate, DAB (Peroxidase Substrate Kit, Vector Labs, Cat.no.: SK-4100) was applied 
for 30 seconds, which was prepared as follows, 
 
 5ml of distilled H2O 
 2 drops of Buffer Stock Solution 
 4 drops of DAB Stock Solution 
 2 drops of Hydrogen Peroxide Solution. 
 
Sections were counterstained with Mayers Hematoxylin for 2 minutes followed by 
dehydration via a series of graded alcohol washes. Coverslips were mounted using DPX 
on a Leica Fully Automated Glass Coverslipper. 
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2.4 PPAR! Expression System 
 
PPAR! transgenic mice were already available in this laboratory upon starting this 
work. Full length human PPAR! was cloned into mice downstream of a CYP1A1 
promoter as follows. Plasmids encoding human PPAR! were prepared and the PPAR! 
coding sequence was amplified using primers PRMG15 (5’-
CTAGTCTAGAATGGAGCAGCCACAGGAGGAAGC-3’) and PRMG3 (5’-
CTAGTCTAGATTAGTACATGTCCTTGTAGATCTCCTG-3’). PCR products were 
cleaved using XbaI and cloned into plasmid pUHD10-3 shown in Figure 2.1. 
 
 
Figure 2.1: Plasmid Orientation Of pUHD10-3 Used For PPAR! Cloning. 
Unpublished data from M. Gossen.  
Image from http://www.zmbh.uni-heidelberg.de/bujard/reporter/pUHD10-3.html. 
 
 
 
 
 
46 
The resultant plasmid was pMGD7. Inserts were confirmed by sequencing, then cleaved 
out using BamHI and ligated into plasmid pAHIRI-"-gal (shown in figure 2.2), which 
was then cleaved with BglII, thus removing the "-galactosidase reporter gene. This 
plasmid was designated pMGD72. 
 
 
Figure 2.2: Plasmid Orientation Of pAHIRI-"-gal. The plasmid contains a region of 
the rat CYP1A1, pA, polyadenylation site; Ori, origin of replication; and Ap, the 
ampicillin resistance gene. It also contains a "-galactosidase reporter gene ("-gal) to 
produce pAHIR1"-gal (Campbell et al 1996). 
 
The orientation of the inserts were confirmed by restriction endonuclease analysis and 
sequencing to ensure the inserts were ligated in the correct order. The plasmid pMGD72 
was then microinjected into pro-nuclei of C57 Black 6 mice crossed with CBA F1 
fertilised eggs. 
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2.5 DNA Extraction And PPAR! Genotyping 
 
Ear tags were obtained from all mice in the line in preparation for genotyping and to 
assign a unique number to each mouse so that they were easily identifiable from 
littermates. Mice were tagged according to the designation shown in Figure 2.3. 
 
 
Figure 2.3: Ear Designations For Mouse Identification. All mice in litters underwent 
ear tagging for genotyping and identification purposes. Shown above is the guide 
according to which all mice were ear tagged. 
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Following collection of ear tags, DNA was extracted using the Macherey-Nagel 
Nucleospin Tissue kit. Ear tags were incubated overnight at 56°C with vortexing in an 
Eppendorf Thermomixer Comfort, suspended in 180µl T1 buffer with 25µl of 
Proteinase K solution added. Samples must be fully covered with buffer and tubes were 
flicked to ensure this. Samples were lysed with the addition of 200µl Buffer B3 and 
heated at 70°C for 10 minutes. DNA binding conditions were adjusted via the addition 
of 210µl of 96-100% ethanol. Samples were thoroughly mixed via aspiration with a 
pipette before being transferred to a NucleoSpin® Tissue Column. The column was 
then centrifuged for 1 minute at 11,000g and the flow-through discarded. The silica 
membrane was washed twice, once with Buffer BW followed by centrifugation, then 
with Buffer B5 followed by centrifugation, with the flow-through discarded each time. 
Centrifuging for 1 minute at 11,000g dried the membrane. Columns were transferred to 
a 1.5ml microcentrifuge tube and DNA was eluted by the addition of 40µl of 
prewarmed (70°C) Buffer BE. Samples were incubated at room temperature for 3 
minutes then centrifuged for 1 minute at 11,000g. Eluted DNA was stored at -20°C until 
use. Resultant DNA Concentrations from the ear tags were determined using a 
NanoDrop 2000 Spectrophotometer. The amount of sample needed to give 20ng of 
DNA was then calculated and used in a PCR reaction. The way this was calculated is 
shown in table 2 
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Mouse 
number 
DNA 
Concentration 
(ng/µl) 
µl DNA(20ng) µl H2O (to 
2.5µl) 
DNA Total 
(ng) 
n x =20/x =2.5-(20/x) =x*(20/x) 
 
Table 2: Calculation To Determine Amount Of Sample Needed To Yield 20ng Of 
DNA For PCR. DNA concentration used is an average of at least 2 similar values with 
a standard deviation of less than 1. 
 
Samples were pipetted into 0.2ml PCR tubes to give a total volume of 2.5µl. A master 
mix containing H2O, 10X CoralLoad PCR Buffer, 5X Q-Solution, dNTP mix, primers 
mix and HotStarTaq Plus Polymerase was added to each sample. These reagents were 
from Qiagen (HotStarTaq DNA Polymerase, Cat.no.: 203203), selected for minimal 
optimization needed and that can deal with the large PCR product generated by the 
primers.  The amounts of each reagent added was as follows, 
 
 For 1 sample, 
 13.8µl H2O (to 25µl) 
 2.5µl 10X CoralLoad PCR Buffer 
 5µl 5X Q-solution 
 0.5µl dNTP (10µM each) 
 0.5µl Primers (356pRMG160 + 355pRMG159, 10µM each) 
 0.2µl HotStarTaq Plus Polymerase (=1U) 
------------------------------------------------------------------------------------- 
22.5µl master mix per sample 
+ 2.5µl DNA 
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Primer Name Sequence 
355pRMG159-R 5’-CCAACCACCCTGTCCCAGCTTG-3’ 
356pRMG160-F 5’-ACAAACTCTGCCCTGCTCTATG-3’ 
 
Table 3: Primers Used In PPAR! Transgenic Mice Genotyping. 
 
Samples were then run on a BioRad C1000 Thermal Cycler on the following program, 
 1: 95°C for 5 minutes 
 2. 94°C for 5 minutes 
 3. 60°C for 30 seconds 
 4. 72°C for 2 minutes 
 5. Go to 2 for 39 times 
 6. 72°C for 10 minutes 
 7. 4°C forever. 
 
Products from the PCR were analysed using gel electrophoresis. Agarose gels were 
prepared by dissolving 2% (w/v) of Ultrapure® Agarose (Invitrogen, Cat.no.: 16500-
500) in 1X TBE. Agarose was dissolved by heating in a microwave on high power until 
the powder was dissolved. Liquid agarose was then cooled to approx. 55°C, then 
SYBR® Safe DNA gel stain (Invitrogen, Cat.no.: S33102) was added, 10µl per 100ml. 
The liquid agarose was then poured into a gel cast, ensuring that no air bubbles form, 
before a comb was inserted and the gel allowed to set. PCR products were added to each 
well, 10µl per well. A 100bp DNA marker (Invitrogen, Cat.no.: 15628-019) was added 
in an adjacent lane to verify PCR product size. The gel was run at a constant of 120 
milliampere for 40 minutes to 1 hour. Gels were analysed using UVIPRO Silver CCD 
camera with UV capability to visualize DNA bands on the gel. 
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2.6 PPAR! Immunohistochemistry – Mouse Tissue 
 
Mice were fed on a 0.003% GW501516 powder diet for 2 weeks before being 
terminated in accordance with Schedule 1 killing procedures as set by the UK Home 
Office. Mice were killed either by cervical dislocation or in a CO2 gas chamber. Organs 
were harvested by dissection, or in the case of the skin, shaved then dissected. All 
tissues were immediately stored in 10% formalin to preserve their structure and overall 
integrity. Samples were then given to Tayside Tissue Bank for paraffin embedding and 
sectioning. Sectioning, deparaffinisation, antigen retrieval and hydrogen peroxide 
protocols were the same as those used for human tissue. 
 
Sections were washed with PBS in between incubation steps. Following washing, 
sections were incubated with a blocking solution (2.5ml PBS + 2 drops M.O.M Mouse 
Ig Blocking reagent stock solution) prepared from the M.O.M Immunodetection Kit – 
Peroxidase (Vector Labs, Cat.no.: PK-2200) for 1 hour at room and then incubated with 
diluent (7.5ml PBS + 600µl Protein Concentrate stock solution = M.O.M diluent) for 5 
minutes at room temperature. Excess diluent was blotted from the slides and primary 
antibody was added (1:1000 in M.O.M diluent, see table 1 for antibody details) to each 
slide and then incubated for 30 minutes at room temperature. Secondary antibody 
(2.5ml M.O.M diluent + 10µl M.O.M Biotinylated Anti-Mouse IgG reagent stock 
solution) was added to the sections, which were incubated at room temperature for 10 
minutes. Sections were incubated with ABC reagent as outlined in section 2.4. 
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2.7 Preparation Of GW501516 Diet For In Vivo Experiments 
 
A concentrated stock of 0.3% GW501516 (w/w, custom – synthesised by AF- 
Pharmaceuticals, UK, to &98% purity) in powder diet was prepared. All subsequent diet 
was made by diluting the concentrated stock. All in vivo experiments were performed 
using 0.003% GW501516 diet unless otherwise stated. To make 500g of 0.003% diet, 
the following was carried out. 
 
It was calculated how much 0.3% stock would be needed to give a final concentration 
of 0.003% in 500g. The amount of GW501516 in 0.3% stock is 0.3g in 100g, therefore 
for a 0.003% diet, it would be 0.003g in 100g, meaning 0.015g in 500g. Thus the 
amount of 0.3% stock needed to yield 0.015g is 5g. This amount of concentrated diet 
was weighed out and made up to 500g with normal RMI diet (supplied in house by 
Medical Resource Unit). This mix was transferred to a blender and mixed for 10 
minutes to ensure homogeneous reconstitution. Once mixed, the diet was transferred to 
a container and stored at 4°C when not in use. 
 
2.8 Recording Of Phenotype – Clinical Photographs 
 
For the taking of photographs to document the phenotype observed upon systemic 
induction with GW501516 containing diet, mice were manually restrained by scruffing 
of the neck with the index and middle finger, followed by securement of the tail by 
additional fingers. Feet were restrained as needed by remaining free fingers. Mice were 
held against a plain background for photographing. In addition, before each mouse was 
photographed, the cage card for that particular cage was also photographed to identify 
mice in the experiment. 
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2.9 H&E Histology 
 
Samples were collected as described in section 2.6 and prepared as described in section 
2.4. The H&E histology was performed using a Leica Autostainer provided by Tayside 
Tissue Bank. Deparaffinisation was performed as described previously. Sections were 
washed with H2O followed with staining with Harris’ Haematoxylin. Wash 2 with H2O. 
Sections were incubated in 0.1% acid alcohol for 1 minute followed by a 3rd wash with 
H2O. Sections were then incubated in STWS for 1 minute followed by a 4th wash with 
H2O. Sections were additionally stained with Shandon Eosin for 30 seconds followed 
by a 5th wash with H2O. Sections were rehydrated and coverslips mounted as described 
in section 2.4 
 
2.10 CD4+, CD8+, CD11c+ And CD31+ Immunohistochemistry 
 
Tissues were harvested from mice after 2 weeks of systemic induction with 0.003% 
GW501516 diet. Following termination, skin on the abdomen of mice was shaved to 
remove any hair that may be still present. Biopsies of skin were taken and immediately 
embedded in O.C.T and snap frozen in liquid N2. Samples were stored at -80°C until 
use.  
 
Samples were orientated and embedded further onto a metal chuck that fits onto a 
cryostat. Samples were sectioned at 5 microns thick and mounted onto Superfrost Plus 
slides (VWR International Ltd, Cat.no.: 631-9483). Following mounting onto slides, 
sections were dried at room temperature overnight. 
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Sections were fixed in ice-cold acetone for 10 minutes then dried for 15 minutes at 
room temperature. Sections were washed following each incubation with PBS. Sections 
were then incubated with 0.3% H2O2 for 10 minutes at room temperature followed by 
blocking using 0.8% FCS in PBS for 30 minutes at room temperature. Following 
blocking, excess serum was blotted from sections before incubation with primary 
antibodies, detailed in Table 4. Each antibody was used at a 1:50 dilution in the 
blocking buffer and incubated for 1 hour at room temperature. 
 
Antibody Manufacturer  
Purified Rat Anti-Mouse CD4 (Monoclonal) BD Biosciences, Cat.no.: 550278 
Purified Rat Anti-Mouse CD8a (Monoclonal) BD Biosciences, Cat.no.: 550281 
Purified Hamster Anti-Mouse CD11c (Monoclonal) BD Biosciences, Cat.no.: 550283 
Purified Rat Anti-Mouse CD31 (Monoclonal) BD Biosciences, Cat.no.: 550274 
Biotinylated Goat Anti-Rat Ig (Polyclonal) BD Bioscience, Cat.no.: 551013 
Biotinylated Anti-Hamster IgG (Polyclonal) BD Bioscience, Cat.no.: 551012 
 
Table 4: Antibodies Used For Immunological Immunohistochemical Analysis. All 
antibodies were used on mouse tissue only. 
 
Following incubation of sections with primary antibodies, sections were incubated with 
secondary antibodies, diluted 1:50 in blocking buffer for 30 minutes at room 
temperature. Details of antibodies that were used are shown in Table 4. After secondary 
antibody incubation, sections were incubated with Streptavidin-HRP (contained in both 
Anti-rat Ig HRP Detection kit and Anti-hamster Ig HRP Detection kit, details in Table 
4) for 30 minutes at room temperature. Positive staining was visualised as previously 
described for PPAR! immunohistochemistry. 
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2.11 Western Blotting 
 
Samples were collected from mice as previously described. Abdominal skin samples 
were immediately snap frozen and stored at -80°C until use. Once frozen, samples were 
homogenised under liquid N2. This involved transferring a skin sample to a 2ml round 
bottomed Eppendorf tube. Once transferred, samples were immediately put back into 
liquid N2 to ensure sample is sufficiently frozen. Samples were dipped into liquid N2 
with the lid open to allow a small amount of liquid to enter the tube. Meanwhile a large 
metal pestal that was shaped for the bottom of the 2ml tubes was cooled using liquid N2. 
Using the pre-cooled pestal, samples were ground to a fine powder, ensuring to keep 
dipping samples into the liquid N2 to keep them frozen. 
 
Following tissue homogenisation, each sample was weighed to determine the exact 
weight of tissue present, then 5µl per mg of tissue of B* buffer was added, which was 
developed and described by Klose et al (Klose 1999) (B* buffer contains 960µl of 
Buffer B/Chaps + 40µl of 25x Proteinase Inhibitor cocktail stock. Buffer B contains 
100mM phosphate buffer, pH =7.4, 20% glycerol and 0.2M KCl. 900µl of this stock 
was taken and 73mg of CHAPS added and 31µl of H2O). To the samples containing B* 
buffer, 1µl of highly concentrated DNase was added. 3 glass beads were then added and 
samples were sonicated 5 x 10 seconds on ice. Samples were then centrifuged at 
20,000rpm (approx. 30,000g) for 5minutes at 4˚C. Supernatant was removed and stored 
in a fresh pre-chilled Eppendorf tube. Following protein extraction, the concentration of 
resultant protein was determined by using Qubit Protein Assay Kit (Invitrogen, Cat.no.: 
Q33211) or by BCA Protein Assay Kit (Pierce, Cat.no.: 23225). 
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For SDS-Page analysis, gels were cast using BioRad 1.0mm spacer plates (BioRad, 
Cat.no.: 1653311) with BioRad short plates (BioRad, Cat.no.: 1653308). Gels were cast 
according to the following composition, shown in table 5 and table 6. In between 
separating gel and stacking gel casting, isopropanol was added on top of the separating 
gel to ensure that samples produced an even, straight band. 
 
Separating Gel 
30ml 
 
5% 7.5% 8% 10% 11% 12.5% 15% 18% 
H2O 17ml 14.5ml 14ml 12ml 11ml 9.5ml 7ml 4ml 
Separating Buffer 
(1.5M Tris-HCl, pH=8.8) 
7.5ml 7.5ml 7.5ml 7.5ml 7.5ml 7.5ml 7.5ml 7.5ml 
30% Acrylamide 
37.5:1 ratio 
5ml 7.5ml 8ml 10ml 11ml 12.5ml 15ml 18ml 
10% SDS 300µl 300µl 300µl 300µl 300µl 300µl 300µl 300µl 
TEMED 10µl 10µl 10µl 10µl 10µl 10µl 10µl 10µl 
10% APS 200µl 200µl 200µl 200µl 200µl 200µl 200µl 200µl 
 
Table 5: Composition Of Separating Gel For SDS-Page Gel Electrophoresis. 
 
 
Stacking Gel 
4% 
 
6ml 12ml 24ml 
H2O 3.5ml 7ml 14ml 
Stacking Buffer 
(0.5M Tris-HCl, pH=6.8) 
1.5ml 3ml 6ml 
30% Acrylamide 
37.5:1 ratio 
800µl 1.6ml 3.2ml 
10% SDS 60µl 120µl 240µl 
TEMED 6µl 12µl 24µl 
10% APS 120µl 240µl 480µl 
 
 
 Table 6: Composition Of Stacking Gel For SDS-Page Gel Electrophoresis. 
 
 
Samples were prepared by pipetting 40µg of protein, adding H2O to 22.5µl then adding 
7.5µl of Laemmli Sample Buffer (BioRad, Cat.no.: 161-0737). Samples were heated at 
99° for 5 minutes, then allowed to cool to room temperature before being added to the 
gel. Into the first two lanes of each gel, 5µl of Precision Plus Protein Kaliedoscope 
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Standard (BioRad, Cat.no.: 161-0375) and 5µl of MagicMark™ XP Western Protein 
Standard (Invitrogen, Cat.no.: LC5602) were added for comparison of size of resultant 
bands. Gels were run for 1-2 hours at constant 0.02A, 40W. 
 
Following SDS-Page to separate the proteins into their respective sizes, proteins in the 
gel were blotted onto Nitrocellulose membrane. The following set-up was used, 6 x 
Whatman papers, Nitrocellulose membrane, SDS-Page gel, 6 x Whatman paper. Prior to 
the gel being lain on top of the nitrocellulose membrane, the Whatman papers and 
membrane were pre-soaked in 1X Blotting Buffer (25mM TRIS-HCl 150mM Glycine 
10% (v/v) Methanol) for 5 minutes. The membrane had additional 1X Blotting buffer 
added once orientated to prevent drying out before the gel was laid on top. This western 
blot sandwich was then placed in a BioRad semi-dry blotter and ran at constant 0.2A, 
20W, 30V for 1 hour. Following blotting, membranes were incubated with Ponceau S 
stain for 5 minutes to ensure transfer had been successful. Images of Ponceau S stained 
membranes were recorded using an HP Scanner. 
 
Membranes were washed with TBST following each incubation. They were then 
blocked for 30 minutes at room temperature with gentle shaking in 4% milk/TBST 
solution. Following blocking, membranes were incubated overnight at 4°C with gentle 
shaking with primary antibody diluted 1:1000 in 4% milk/TBST solution. Details of 
antibodies used in western blot analysis are shown in table 7. 
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Antibody Manufacturer 
Phospho-Stat3 (Tyr705) (D3A7) Rabbit 
Monoclonal Antibody 
Cell Signalling, Cat.no.: 9145S 
Stat3 Polyclonal Antibody  Cell Signalling, Cat. No.: 9132 
Monoclonal Anti-GAPDH antibody 
produced in mouse, clone GAPDH-71.1,  
Sigma, Cat.no.: G8795 
ECL anti rabbit IgG, HRP conjugated 
(Polyclonal) 
GE Healthcare, Cat.no.: NA934 
Sheep polyclonal Secondary Antibody to 
Mouse IgG - H&L (HRP) 
Abcam, Cat.no.: ab6808 
 
Table 7: Antibodies Used In Western Blotting Analysis. 
 
After incubation with primary antibodies, membranes were incubated with secondary 
antibody at a dilution of 1:2000 in 4% milk/TBST for 30 minutes at room temperature 
with gentle shaking. Excess TBST was removed from the membrane before being 
placed on a petri dish and ECL Plus (Amersham ECL PlusTM Western Blotting 
Detection Reagents, GE Healthcare, Cat.no.: RPN2132) was added and incubated in the 
dark for 5 minutes at room temperature. Excess ECL Plus was removed from the blot, 
which was then placed in a plastic sleeve before being exposed with a CCD camera with 
chemiluminescence capability. 
 
After chemiluminescence for STAT3 and phospho-STAT3, membranes were washed 
three times with TBST for 5 minutes each after exposure then incubated with 1:1000 
dilution of GAPDH in 4% milk/TBST for 1 hour at room temperature with gentle 
shaking. Membranes were then incubated with 1:2000 dilution in 4% milk/TBST of 
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secondary antibody for 10 minutes at room temperature with gentle shaking. 
Membranes were exposed and recorded as described in section 2.11. 
 
2.12 Phospho-STAT3 Immunofluorescence 
 
Frozen sections were prepared as previously described for immunological stainings 
using a cyrostat. Sections were incubated in ice-cold methanol for 15 minutes at -20°C. 
Following methanol fixation, slides were dried at room temperature for 15 minutes. 
Sections were washed with TBS following each incubation. To minimise the amount of 
antibody used, a waterproof barrier was drawn around the section on the slide using a 
Liquid Blocker Super Pap Pen. Sections were then incubated for 1 hour with blocking 
buffer (10% goat serum, 1% BSA, 0.3M Glycine) to reduce any non-specific 
background staining. Excess blocking buffer was blotted from sections which were then 
incubated with 1:50 dilution of Phospho-Stat3 antibody or 1:50 Phospho-Stat3 antibody 
+ 1:100 Phospho-STAT3 Blocking Peptide in 1% BSA/TBS for 1 hour at room 
temperature. Following primary antibody incubation, sections were then incubated with 
secondary antibody, diluted 1:2000 in 1% BSA/TBS for 10 minutes at room 
temperature. See table 8 for antibody and blocking peptide details. 
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Antibody Manufacturer 
Phospho-Stat3 (Tyr705) (D3A7) Rabbit 
Monoclonal Antibody 
Cell Signalling, Cat.no.: 9145S 
Phospho-Stat3 (Tyr705) Blocking Peptide Cell Signalling, Cat.no.: 1195 
Alexa Fluor® 488 donkey anti-rabbit IgG 
(H+L) (Polyclonal) 
Invitrogen, Cat.no.: A-21202 
 
Table 8: Antibodies Used In Immunofluorescence. 
 
Following secondary antibody incubation, a small amount of ProLong® Gold antifade 
reagent with DAPI (Invitrogen, Cat.no.: P-36931) was added to the coverslip before 
being applied to the section. Sections were dried overnight in the dark before being 
sealed with clear nail polish and visualised using a fluorescent microscope which 
utilises oil to aid the focusing of the objectives. 
 
2.13 WP1066 Treatment 
 
10mg of WP1066 was dissolved into a solution containing DMSO and PEG300 in a 20 
to 80 parts ratio to give a final concentration of 1.25µg/µl. This was achieved by 
centrifuging the WP1066 containing vial to ensure the entire drug was at the bottom. 
DMSO/PEG300 (20/80) was then added to the vial, which was sealed and vortexed 
until the entire drug had dissolved. Mice were administered 75µl of 1.25µg/µl solution 
of WP1066 or 75µl of DMSO/PEG300 (20/80) via intraperitoneal injection as described 
by Kong et al (Kong et al 2008). This was done three times weekly, in the morning to 
enable mice to be monitored throughout the day in case of any adverse effects. While 
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receiving injections of WP1066, mice were also being systemically induced with 
GW501516. H&E histology was performed as previously described. 
 
2.14 TaqMAN Gene Expression Analysis 
 
Sample sections were collected and processed as described in section 2.11. The 
following protocol was followed from Machery-Nagel RNA II Total RNA Isolation kit 
(Fisher Scientific, Cat.no.: NZ740955250). Lysis buffer, containing RA1 buffer and "-
mercaptoethanol, was added to the samples, which were then vortexed vigorously. The 
lysate was filtered via centrifugation then RNA binding conditions adjusted through the 
addition of 70% ethanol. Samples were then loaded on to a new column and filtered via 
centrifugation. This ensured that RNA was then bound to the column membrane. The 
membrane was then desalted via addition of Membrane Desalting Buffer to maximise 
the efficiency of the DNase treatment. Samples were then incubated with an RNase free 
DNase for 15 minutes at room temperature, followed by a series of washes and drying 
of the membrane. RNA was eluted with RNase-free H2O then snap-frozen and stored at 
-80°C. 
 
RNA concentration was determined using the Qubit RNA Assay Kit (Invitrogen, 
Cat.no.: Q32855). Approximately 200-400ng of RNA was used to synthesis cDNA 
using a cDNA synthesis kit (SuperScript® VILO™ cDNA Synthesis Kit, Invitrogen, 
Cat.no.: 11754-050). For a single reaction, the following was done, 
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5X VILO™ Reaction Mix     4µl 
10X SuperScript® Enzyme Mix    2µl 
RNA               2.5µg 
DEPC-treated water          to 20µl. 
 
Once samples had been prepared for the reaction, they were put on the following 
program on a BioRad C1000 Thermo Cycler, 
 
 25°C for 10 minutes 
 42°C for 60 minutes 
 85°C for 5 minutes. 
 
Approximately 2µl of cDNA was added in triplicate for each sample into each well on a 
96-well PCR plate. Samples were analysed for IFI27, GAPDH and IL-1". The details of 
the primers used are shown in table 9. 
 
Primer Name Sequence 
mGAPDH-F 5’-GCCAAGGTCATCCATGACAAC-3’ 
mGAPDH-R 5’-GGGGCCATCCACAGTCTTC-3’ 
mGAPDH-FAM 5’-[6- 
FAM]CTCATGACCACAGTCCATGCCATCACT[TamraQ]-3’ 
IL-1" Mm01336189_m1 IL1b (Applied Biosciences) 
IFI27 Mm01329883_gH If127 (Applied Biosciences) 
 
Table 9: Primers Used In Taqman Gene Expression. 
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Master mix containing primers and H2O was added to each sample to make the final 
reaction volume 15µl, according to the following protocol, 
 
 For GAPDH (1 sample) 
H2O      7.375µl 
 Forward primer     0.375µl 
 Reverse primer    0.375µl 
 Probe      0.375µl 
 TaqMan® Universal PCR Master Mix     4.5µl 
 (Applied Biosystems, Cat.no.: 4304437) 
For IL-1" and IFI27 (1 sample) 
H2O      7.75µl 
 Primer Mix     0.75µl 
 TaqMan® Universal PCR Master Mix   4.5µl 
 (Applied Biosystems, Cat.no.: 4304437) 
 
PCR Plates were then sealed and run on a TaqMAN PCR Machine on the following 
program, 
1. 50°C for 2 minutes – Segment 1 
2. 95°C for 10 minutes – Segment 2 
3. 95°C for 15 seconds – Segment 3 
4. 60°C for 1 minute – Segment 3 
Segment 3 is repeated for 40 cycles. 
 
Upon finishing, data was analysed on an accompanying computer and used to generate 
the graphs shown in Results. 
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3. Results 
 
3.1 Characterisation Of An In Vivo Model For The Skin Disease Psoriasis 
 
3.1.1 Expression Of PPAR! In Human Skin 
 
Previous work by our lab had established and reconfirmed the upregulation of PPAR! 
mRNA in psoriatic skin lesions by analysis of global expression in two independent 
cohorts, totalling 58 paired lesional and non-lesional data sets, revealing that PPAR! is 
upregulated whereas the other two PPAR isoforms, # and $, are downregulated 
(Romanowska et al 2010) (see Introduction). To verify the localisation of PPAR! 
expression and distribution on the protein level in both normal human skin and 
psoriasis-affected skin, immunohistochemistry was performed on skin sections from 
both groups. This revealed that in normal skin, PPAR! was predominantly expressed in 
the cytosol in the lower epidermis (Figure 3.1 A). In contrast, in psoriasis-plaques, 
PPAR! is additionally strongly expressed in the nucleus and in the upper spinous layer 
(Figure 3.1 B). This was highly reproducible, being observed in eight different patient 
samples (supplementary figures of (Romanowska et al 2010)). Figure 3.1C shows the 
negative control, confirming that the expression of PPAR! observed is specific. These 
results confirm the previously noted overexpression of PPAR! in psoriasis. Based on 
the observed maximal nuclear expression in the upper spinous layer, these results 
suggest that PPAR! may regulate late epidermal differentiation. 
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Figure 3.1: Immunohistochemistry Shows Cytosolic PPAR! Expression In Normal 
Human Skin And Is Over-Expressed In The Nucleus In Psoriatic Skin. 
Immunohistochemical PPAR! staining of paraffin-embedded human skin. Normal 
human skin (A) shows PPAR! expression in the lower epidermis, with a cytosolic 
expression pattern. Psoriasis (B) shows nuclear accumulation of PPAR! in the spinous 
layer, with some peri-nuclear staining, the reason for which is unknown. The negative 
control (C) confirms the specificity of staining. Magnification 200x. 
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 3.1.2 Expression System Design For In Vivo Targeted Overexpression Of PPAR! 
 
In order to characterise the function of PPAR! in upper epidermal layers, our group 
took advantage of an already available transgenic mouse strain expressing PPAR!. This 
transgenic line expresses human PPAR! under the control of the rat CYP1A1 enhancer 
resulting in specific expression of the transgene in the skin, as follows (schematic 
shown in figure 3.2). Within the CYP1A1 enhancer, two regulatory elements are 
contained. First, there is a DXE/XRE sequence cluster responsive to binding of the aryl-
hydrocarbon receptor (AhR). For AhR to bind DXE/XRE, it must in turn be activated 
by specific ligands, such as indole-3-carbinole (I3C). Thus, drugs such as I3C can 
induce transgene expression in tissue such as liver, which was the original purpose of 
the model. Second, apart from transactivation by AhR, the same enhancer is 
constitutively active in sebaceous glands (Rowe et al 2008). This AhR-independent 
selective high-level transgene expression is mediated by a cis-acting G/C rich enhancer 
element in the CYP1A1 promoter, which has been previously found to drive strong 
sebaceous gland expression (Kaufman et al 2002). Thus, under untreated conditions, 
PPAR! transgenic mice express the transgene specifically in the sebaceous glands 
(figure 3.2). Upon administration of a PPAR! specific ligand, GW501516, this 
expression becomes more widespread in the overlying epidermis. The mechanism 
underlying this secondary induction is the known activity of PPAR! in stimulating the 
differentiation of sebocytes (Michalik and Wahli 2007) and delivery of sebum to the 
skin (Trivedi et al 2006). The sebum produced, in turn, is rich in ligands capable of 
activating AhR, such as 15-epi-lipoxin A4 (LXA4) and 5,6-dihydroxy-7,9-trans-11,14-
cis-eicosatetraenoic acid (5,6 – DiHETE). Once activated by these ligands, AhR is 
therefore able to transactivate the expression of the PPAR! transgene in the epidermis 
via an interaction between the AhR and the DXE/XRE responsive element in the 
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CYP1A1 enhancer. The net effect is an inducible expression of PPAR! in the epidermis 
upon administration of the PPAR!-activating ligand GW501516, as summarised in 
figure 3.2. 
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Figure 3.2: System For Inducible Skin-Targeted PPAR! Expression In Vivo And 
Activation Of Transgene In Murine Epidermis. Schematic representation of PPAR! 
transgenic induction system. PPAR! is highly and constitutively expressed in the 
sebaceous glands of these mice due to the presence of a highly conserved G/C rich box 
that confers homology to genes specific for the sebaceous glands. Using GW501516 to 
activate PPAR!, the sebocytes differentiate and produce sebum, which contains 
endogenous ligands for the AhR which is fused to the CYP1a1 promoter. This drives the 
expression of PPAR! throughout the epidermis. Modified from (Romanowska et al 
2010). 
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3.1.3 Detection Of Transgene In Animal Model 
 
Following the generation and expansion of the transgenic line, mice were genotyped to 
determine transgenic status. Ear tags were taken from each mouse in the litter and the 
DNA extracted (see Methods and Materials). Once extracted, the DNA was then 
subjected to PCR analysis using primers specific for the transgene inserted in the mice. 
The PCR product was analysed by gel electrophoresis. Transgenic status was 
determined by the presence or absence of a 1.4kb band shown on the gel (figure 3.3), 
verified by a positive and negative control. Those expressing a positive result were 
deemed transgenic and those negative were deemed wild type. Based on these results, 
mice expressing the transgene were selected for experiments, identified by their ear tag 
status. 
 
Figure 3.3 PCR Amplification Of PPAR! Transgene From Ear Skin DNA 
Distinguishes Murine Trangenic From Non-Transgenic Littermates. 20ng of DNA 
extracted from mouse ear tags was subjected to PCR analysis with primers recognising 
human PPAR!. The gel shown is typical for all mice analysed. All mice positive for 
transgene show a band approx. 1.4kb. Note sample 650, which is not positive and is 
most likely due to contamination, as it is a fainter band compared to the other positive 
results shown. 
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3.1.4 Specificity Of PPAR! Expression 
 
Once the expression of PPAR! following induction in transgenic mice had been 
verified, the “leakiness” of the induction system was then investigated, i.e. if there was 
PPAR! expression elsewhere in the mice. A variety of organs were checked, 
specifically ones that are known to express PPAR! in humans. The colon, liver, muscle, 
spleen and lymph node of control transgenics and induced transgenics were subjected to 
immunohistochemistry analysis, staining for human PPAR!. As shown in figure 3.4, 
there was no staining for PPAR! in any of the organs studied, in either control 
transgenics or induced transgenics. This confirmed that the induction system described 
above was tightly controlled, with constitutive expression only occurring in the 
sebaceous glands and following initiation with GW501516, in the epidermis. 
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Figure 3.4 Immunohistochemistry Staining Of Colon, Liver, Muscle, Spleen And 
Lymph Node Reveal Specific PPAR! Expression Is Only Observed In Skin Following 
Activation. Immunohistochemistry of paraffin-embedded organ sections. Sections were 
stained for PPAR! to verify the specificity of the expression system used in the model. 
As can be observed, there is little to no positive staining for PPAR! in all organs 
examined. Skin is included as a positive control. Magnification 200x. 
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3.1.5 Phenotype Of PPAR! Transgenic Mice Upon Induction 
 
Mice were induced with GW501516, a specific PPAR! agonist, diluted in powdered 
diet at a concentration of 0.003% for 2 weeks. The results revealed a specific skin 
phenotype in mice treated with GW501516 diet compared to control mice. GW501516 
treated mice showed scaling, inflammation and skin thickening (figure 3.3). 
Hyperkeratosis (indicated by skin roughening) and hair loss was observed, primarily in 
regions that are subjected to mechanical friction such as the abdomen, paws and chin 
(figure 3.3). The development of these changes on sites of mechanical friction is 
reminiscent of plaque formation in patients with psoriasis. Some mice also developed 
psoriasis-like plaques on the back, however skin changes in the majority of mice were 
limited to scaling on the dorsal skin. A minor phenotype that is also observed in mice 
induced with GW501516 is weight loss and is observed in all mice studied. Since this is 
a well-documented metabolic effect of GW501516, this phenotype was not further 
investigated (Harrington et al 2007, Tanaka et al 2003). 
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Figure 3.5: Following Induction, PPAR! Transgenic Mice Show A Psoriasis-Like 
Phenotype. Clinical photographs detailing the phenotype of PPAR! transgenic mice 
after induction with GW501516 for 20 days. These images are representative of all 
transgenic animals treated with GW501516. Note in the middle panel the formation of a 
“psoriatic” plaque on the back skin. Mice were manually restrained which creates 
artificial tightening of the skin. 
 
Histologically, mice induced with GW501516 show marked epidermal thickening 
compared to non-treated controls (figure 3.6). This is accompanied with dilation of 
dermal blood vessels and the increased abundance of lymphocytes. In contrast to 
psoriasis in humans, the granular layer is still present in the skin of these mice. This can 
be explained by the known role of PPAR! in epidermal differentiation (Schmuth et al 
2008). Although the basic phenotype shows 100% penetrance, there is variability in the 
degree of epidermal hyperproliferation observed in mice induced with GW. The most 
likely explanation for this is biological variability. Even though the used transgenic 
strain is “inbred” this only means near-identity in the HLA-system. The remaining 
genome continues to differ between individual mice. In addition, body weight may be a 
factor, i.e. if the starting body weight is higher then mice will require more GW501516 
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before they exhibit a phenotype and vice versa. As male C57 Black 6 mice are larger 
than female mice, gender might be a factor however no systematic difference between 
male and female mice has been found in this model. Whatever the cause, it appears that 
mice have natural variation in the degree of phenotype observed. 
 
 
Figure 3.6: H&E Histology Show Epidermal Hyperplasia In GW-Induced Mice 
Compared To Wild-Type Controls. Comparison of H&E histology between WT and 
GW-treated transgenic (tg) skin. The right panel shows skin histology following 
induction for 20 days with GW501516.  
 
3.1.6 Assessment Of PPAR! Expression In Murine Skin 
 
As described above, upon treatment with the specific PPAR! agonist GW501516, mice 
developed a psoriatic-like phenotype (figure 3.3). To assess the specificity of the 
induction system on PPAR! overexpression, immunohistochemistry was performed on 
PPAR! transgenic mice at rest, induced and compared with wild type littermates. As 
expected, there was no transgenic PPAR! expression in wild type skin (figure 3.7B), 
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however in PPAR! transgenics (tg) not induced with GW501516, there was staining of 
PPAR! observed in the sebaceous glands (figure 3.7C), as described, above (section 
3.1.2). Upon induction with GW501516 for 7 days the expression of PPAR! became 
more widespread in the epidermis. The epidermis was also thickened due to the 
stimulatory role of PPAR! on keratinocyte proliferation (figure 3.7D). 
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Figure 3.7: Immunohistochemical Assessment Of PPAR! In Transgenic Murine Skin 
Revealed Expression In Sebaceous Glands Under Resting Conditions And 
Widespread Expression In GW-Induced Mice. Immunohistochemistry for PPAR! in 
murine skin. A shows negative control (PPAR!, non-induced, transgenic abdominal 
skin, treated with secondary antibody only), B panel shows staining for PPAR! in C57 
black 6 wild type (WT) skin, C shows PPAR! staining in PPAR! transgenic and D 
shows PPAR! staining in PPAR! transgenic induced with GW501516 for 7 days. 
Magnification x200. 
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To assess how quickly PPAR! expression was switched on in response to induction 
with GW501516, mice were induced for a total of 7 days with 0.003% GW501516 
diluted in powdered diet and various time points taken. The time points chosen were 
0hrs, 48hrs, 96hrs and 7 days. As early as 48 hours following induction with 
GW501516, protein translation was observed in the epidermis (figure 3.8, middle 
panel). At 96 hours, epidermal changes were already under way with the marked 
thickening of the epidermis and the expression of PPAR! becoming yet more 
widespread. The expression of PPAR! in the sebaceous glands was constitutively high, 
as outlined above, with strong positive staining observed (figure 3.8, upper left panel). 
Notably, after 7 days of induction, the epidermis was markedly thickened compared to 
skin at 0 hours after induction, with PPAR! expression observed throughout the 
epidermis. With this change in the epidermis, a phenotype was also observed in the 
mice similar to that shown in figure 3.5. 
 
 
 
 
 
79 
 
Figure 3.8: Timecourse Induction Reveals Expression Of PPAR! In Skin As Early 
As 48hrs Following Induction By GW501516. Immunohistochemical analysis of 
PPAR! expression at differing time points following GW501516 induction. From left to 
right, top row, 0hrs, 48hrs, 96hrs, bottom row, 7 days after induction and the negative 
staining control (PPAR! non-induced transgenic abdominal skin, with secondary 
antibody only). Magnification 200x. 
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3.1.7 Characterisation Of Immunological Changes In PPAR! Mice 
 
To further compare the phenotype of the mice with respect to known alterations in 
psoriasis, the changes in the levels of immune cells recruited to psoriatic skin were 
measured by immunohistochemistry. As outlined in the Introduction various immune 
cells are recruited to the skin in psoriasis upon the induction of psoriatic plaque 
formation resulting in inflammation. The main cells recruited are CD4+ and CD8+ T 
cells as well CD11c+ dendritic cells. The staining of CD31, which is a marker for 
endothelial activation, suggesting the stimulation of angiogenesis, a key feature of 
psoriasis, was also investigated. All these immunohistochemistry stainings were 
performed on frozen O.C.T embedded skin sections from both control transgenics and 
induced transgenics. In control sections, there are some CD4+ cells detectable in the 
dermis; with the level of these cells increasing in the dermis of transgenic induced with 
GW501516 (figure 3.9, top row). In contrast, CD8+ cells were barely detectable in 
control skin, however there was a modest increase in their levels following induction, 
particularly in the epidermis (figure 3.9, second row). CD11c+ dermal dendritic cells 
were present in low levels in control mice, with numbers increasing in GW501516-
treated mice (figure 3.9, third row). However, there was an absence of CD11c+ 
Langerhans cells, which correlates with the impaired migration observed in psoriasis 
(Cumberbatch et al 2006). Finally, expression of CD31, a marker for endothelial cell 
activation, was increased in GW501516-treated mice compared to the levels observed in 
control mice (figure 3.9, bottom row). All of these changes were analogous to the type 
of infiltrate seen in psoriasis plaques. 
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Figure 3.9: GW501516 Stimulates An Increase In CD4+, CD8+, CD11c+ And CD31+ 
Cells In Skin of GW-Induced Transgenic Mice. Changes observed in CD4, CD8, 
CD11c and CD31 expressing cell numbers in control and GW501516- treated mice. 
Images are representative and taken at 200x magnification.  
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3.2 Characterisation Of STAT3 Involvement In PPAR! In Vivo Model 
 
3.2.1 Expression Of STAT3 And Phospho-STAT3 In Vivo 
 
As detailed in the Introduction, STAT3 is highly activated in psoriasis, indicated by the 
presence of phosphorylated STAT3 in the epidermis (Sano et al 2005). Accordingly, we 
investigated the role of STAT3 in our psoriasis-like animal model. Transgenic mice 
were induced with GW501516 for 2 weeks, and then sacrificed and skin biopsies 
harvested. In parallel, non-induced mice were used as controls. Whole cell protein 
extracts from both non-induced and induced mice were extracted using so-called Klose 
buffer as detailed in Methods. These samples were then subjected to Western Blot 
analysis, which revealed that STAT3 expression was unchanged in both non-induced 
transgenic mice and induced mice (Figure 3.10). However, levels of STAT3 
phosphorylated at Tyr705 (“phospho-STAT3”), the activated form of STAT3, were 
induced with GW501516. When densitometry was applied to western blot results, the 
difference in the protein level of phospho-STAT3 and STAT3 was confirmed, showing 
no change in the level of either protein in the control animals but in the mice induced 
with GW501516, the levels of phospho-STAT3 being greatly upregulated.  
 
Interestingly, there were two bands detectable when probing a blot of whole cell protein 
skin extracts with an anti-STAT3 antibody. These bands were around 4-5 kDa apart, 
with the upper band being 86 kDa in size and the lower around 79 kDa. This double 
band corresponds to the two isoforms STAT3-# (upper) and STAT3-" (lower), 
respectively, as previously described (Maritano et al 2004). Specific 
hyperphosphorylation of STAT3 #, as seen in the figure, was observed in three other 
western blots of whole cell protein skin extracts probed with this antibody. 
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Figure 3.10: Western Blot Analyses Show Hyperphosphorylation Of STAT3 In GW-
Induced Mice. A shows western blot analysis of whole skin extracts probed with STAT3 
and phospho-STAT3 (P-STAT3). B shows densitometry analysis of western blot results. 
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3.2.2 Localisation Of Phospho-STAT3 In The Skin Of PPAR! Transgenic Mice 
Following Induction 
 
In order to determine the localisation of phospho-STAT3 in lesional skin from induced 
mice, an immunoflurorescence protocol was established in the laboratory. Analysis of 
the sections revealed that there was an increase in the presence of phospho-STAT3 in 
GW501516-induced mice only (figure 3.11). The expression of phospho-STAT3 in 
non-induced mice was barely detectable, predominantly due to the skin only being a 
few cell layers thick, therefore making the localisation of phospho-STAT3 difficult to 
detect in frozen sections. The expression of phospho-STAT3 was predominantly 
localised to the nuclei of the suprabasal layer in the lesional skin of induced mice. To 
verify the specificity of staining observed in all sections, phospho-STAT3 was 
competed with a blocking peptide. DAPI staining was also performed to verify the 
nuclear localisation of phospho-STAT3. 
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Figure 3.11: Immunofluorescence Shows That Phospho-STAT3 Is Localised To The 
Nucleus In The Suprabasal Epidermis In GW-Induced Mice. Immunofluorescence of 
5µm frozen sections from induced and non-induced mice treated with anti-phospho-
STAT3 or competed with blocking peptide. Upper panels show GW induced mice, with 
(A) and without (B) DAPI staining, shown to verify nuclear localisation. Lower panels 
show competition with blocking peptide (C) and non-induced skin (D). The white 
dashed line represents the dermal-epidermal barrier. *=hair shaft. All images taken at 
400x magnification. 
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3.2.3 Role Of STAT3 In Disease Progression In Vivo 
 
In order to determine whether STAT3 activation contributes to progression of psoriasis-
like disease in PPAR! mice, transgenic mice were induced with GW501516 in the 
absence or presence of inhibition of STAT3 phosphorylation. As shown in figure 3.12, 
concurrent treatment with the JAK2 inhibitor substantially inhibited the development of 
epidermal hyperproliferation and inflammatory changes. This suggests that STAT3 
phosphorylation may contribute to the development of skin disease induced by PPAR! 
activation. However, due to the lack of full inhibition of development of the phenotype, 
the phenotype observed in these mice cannot solely be attributed to activated STAT3. 
Rather, other molecular players appear to be at work that continue to drive the psoriatic 
phenotype. 
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Figure 3.12: Treatment Of GW-Induced Mice With JAK2 Inhibitor, WP1066 
Partially Inhibits Development Of Epidermal Hyperplasia. H&E histology of 
untreated skin (A), GW501516-treated skin (B) or GW501516 + JAK2 inhibitor (C). 
Treatment with WP1066 partially inhibited the development of disease phenotype. 
Images are representative, taken at 200x magnification. 
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3.2.4 Effect Of JAK2 Inhibition On Gene Expression 
 
A major characteristic of psoriasis is that a group of genes termed the “interferon 
response genes” are upregulated. However, in this particular transgenic model, the 
interferon response genes are actually downregulated (Romanowska et al 2010). 
Notably, it has previously been shown that STAT3 represses the exact same set of genes 
in vivo (Dauer et al 2005). Therefore, we hypothesised that STAT3 activation underlies 
the repression of interferon response genes, such as IFI27, in this model as well. If so, 
their repression should be reversible by JAK2 inhibition. Indeed, JAK2 inhibition did 
show a significant effect on the reversal of IFI27 downregulation (Figure 3.10), IFI27 
being chosen as one of the most strongly downregulated and well characterised IFN 
target genes, thus it partially rescued the expression of IFI27 back to levels comparable 
to those observed in control mice. In contrast, JAK2 inhibition had no effect on IL-1", 
which is situated in another inflammatory pathway, thereby suggesting that STAT3 
activation by JAK2 regulates interferon response genes, but not other inflammatory 
circuits. This result indicates that the interferon-signalling inhibition observed in these 
mice is possibly regulated by STAT3, which has been termed the “anti-inflammatory 
response” (Murray 2006). 
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Figure 3.13: JAK2 Inhibition Results In Partial Rescue Of IFI27 Gene Expression 
With No Effect On Other Inflammatory Pathways. TaqMAN gene expression analysis 
of IFI27 and IL-1" from whole skin of untreated mice (black column), GW-treated mice 
(white column) and GW-treated mice + JAK2 inhibitor (grey column) respectively. (n= 
3 mice per group) * = p<0.05. 
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4. Discussion 
 
4.1 Generation Of In Vivo Model Of Psoriasis 
 
The transgenic mouse model characterised in the course of the present thesis exhibits a 
number of unconventional features meriting discussion. In order to test whether 
activation of PPAR! by itself is sufficient to trigger psoriasis-like skin changes in vivo, 
one could have chosen a different strategy. In the present case, however, a model was 
already available, in which human PPAR! had been placed under the control of the 
CYP1A1 enhancer in order to allow inducible expression in the liver upon 
administration of AhR activating chemicals. Strikingly, and completely unexpected, this 
model also afforded a skin-targeted expression of PPAR!. In addition to AhR-mediated 
inducible expression in the skin, a previously unnoticed enhancer element conferred 
very high constitutive expression in the sebaceous glands, thereby creating a model 
wherein PPAR! was continuously expressed in the sebaceous glands. Two additional 
fortuitous elements were required to turn this sebaceous-specific expression pattern into 
an epidermis-specific inducible model. First, the fact that, in our case, the transgene, 
(PPAR!), happens to be a natural activator of sebaceous gland differentiation and 
sebum production. Thus, simply adding an activating ligand triggered sebum 
production. Second, sebaceous differentiation, sebum production, and the concomitant 
upregulation of lipoxygenases resulted in the delivery of bioactive lipids to the 
epidermis, which in turn transactivated the AhR in the epidermis. Obviously, this 
system was highly unorthodox and it could be argued that it is less “clean” than using a 
standard epidermis – specific controlling promoter. However, a number of key features 
single out this particular model as highly appropriate to model PPAR! activation in 
psoriasis. First, the system is very tightly controlled: no inducible expression is seen in 
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any other tissue outside the skin. Second, the system allowed use of a single chemical, 
GW501516, to achieve both transgene induction and ligand-activation of PPAR!, which 
massively reduced cost and animal numbers by obviating the need for more control 
groups. Third, the expression pattern in the epidermis was distinctively patchy (see 
figure 3.7), which is very similar to the distribution of PPAR! in the nuclei of the 
spinous cell layer in psoriasis plaques. A conventional suprabasal-active promoter (e.g. 
loricrin, involucrin) by contrast would produce a more linear expression pattern and, in 
addition, not allow inducibility. Thus, although a bona fide discovery, the present 
transgenic model is highly suitable to study the effect of PPAR! in the epidermis. 
 
4.2 PPAR! And Inflammation In The Skin 
 
Psoriasis is predominantly an inflammatory skin disease. To date, PPAR! has been 
implicated with a role in inflammatory processes. However, there is a controversial 
debate as to whether it is pro-inflammatory or anti-inflammatory, with evidence 
reported for both (Barish et al 2008, Hall and McDonnell 2007). Based on the results 
presented here, it appears that PPAR! plays a pro-inflammatory role in psoriasis 
(Pollock et al 2010, Romanowska et al 2010). PPAR! induces a specific IL-1 signalling 
module both in psoriasis and PPAR! transgenic mice, which involves pro-inflammatory 
mediators such as IL-1", which has been shown to stimulate Th17 differentiation, a 
major characteristic of psoriasis (Kryczek et al 2007). This IL-1 signalling module also 
contains anti-inflammatory mediators, such as IL-1F5 in fibroblasts, which has been 
shown to inhibit skin disease (Blumberg et al 2007, Magne et al 2006). In addition, the 
IL1 receptor antagonist (IL1RA) has also been shown to be part of this IL1 module, is a 
direct target of PPAR! (Chong et al 2009), and is upregulated in psoriasis (Debets et al 
 
 
93 
1997). Therefore, the role of PPAR! cannot solely be described as pro- or anti-
inflammatory. 
 
4.3 Similarity To Human Disease 
 
 The data presented here confirm that activation of PPAR! is enough to trigger 
inflammatory changes in the skin similar to psoriasis. PPAR! mice showed several 
histological and immunological changes that are synonymous with the human disease. 
As early as 7 days following induction, mice showed enhanced epidermal thickening, 
dilation of dermal blood vessels and increased lymphocytes in the epidermis. In 
addition, the influx of CD4+, CD8+ T cells and CD11c+ dermal dendritic cells, 
expansion of Th17 cells was also abundant in the affected skin of PPAR! mice 
(Romanowska et al 2010). This verifies that PPAR! mice following induction replicate 
several of the key phenotypical changes observed in psoriasis patients. In that respect, 
the immunological changes and STAT3 activation are in line with previous data from 
our lab on this model which revealed a high level of similarity of gene dysregulation 
when compared with expression profiling data sets of psoriasis patients. Shown in 
figure 4.1 is a summary of the top 50 upregulated genes in the PPAR! transgenic mice 
compared with two independent psoriasis cohorts. These data show that the majority of 
genes are upregulated in psoriasis and PPAR! transgenic mice (Romanowska et al 
2010).  
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Figure 4.1: Congruent Gene Dysregulation In PPAR! And Psoriasis. Diagram above 
shows fold change between lesional skin of PPAR! mice and control mice and between 
lesional and non-lesional skin of psoriasis patients obtained from the GAIN (I) and 
GSE14905 (II) psoriasis cohorts, respectively. Red shows a fold change of >1.5 and 
green indicates a fold change of <0.8. The top 50 genes upregulated in psoriasis are 
shown. Modified from (Romanowska et al 2010). 
 
4.4 Differences To Psoriasis 
 
Prior to the establishment of this model, it was an open question whether activation of 
PPAR! in psoriasis is part of the disease process or, on the contrary, represents an 
attempt of the epidermis to combat the psoriatic reaction. The latter would have been 
indicated by data suggesting that PPAR! in fact is anti-inflammatory and blocks cell 
proliferation (Peters et al 2000, Peters and Gonzalez 2009, Romanowska et al 2010). 
Although the model confirms that activation of PPAR! is sufficient to trigger 
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inflammatory changes with great similarity to psoriasis, there are two major differences 
between the transgenic mice and psoriasis. Two clusters of genes were found to be 
differentially regulated when compared to psoriasis (Romanowska et al 2010). The first 
of these clusters contains genes that are upregulated in our model but downregulated in 
psoriasis. This cluster was enriched with markers of late differentiation, such as 
filaggrin (FLG) and protocadherin 21 (PCDH21). The upregulation of these genes 
mirrors the continued presence of the granular layer in PPAR! mice, a histological 
feature that is absent in psoriasis. The known effects of PPAR! on epidermal 
differentiation can explain this feature. Schmuth et al showed that topical application of 
a PPAR! agonist increased markers of differentiation in vivo (Schmuth et al 2004). 
Thus, the continued presence of the granular layer in PPAR! mice can be attributed to 
the prodifferentiation effects that PPAR! exerts on keratinocytes and the epidermis. 
 
The second cluster of genes found to be upregulated in psoriasis but downregulated in 
PPAR! mice contained genes involved in interferon signalling. This may in fact be 
related to the increased levels of activated STAT3 in PPAR! mice after induction of 
disease (section 3.2, also below, section 4.13). To this end, Dauer and colleagues 
showed that STAT3 represses this group of genes in vitro (Dauer et al 2005), thereby 
possibly explaining why this particular set of genes is downregulated in our model, 
which expresses an increased level of activated STAT3 in response to phenotype 
induction with GW501516.  
 
Taken together, activation of PPAR! in the epidermis leads to psoriasis-like 
inflammatory and immunological changes, which may be in part mediated via STAT3 
signalling (see below, section 4.13). On the other hand, the block in terminal 
differentiation, which is characteristic of psoriasis, does not occur in these mice. Indeed, 
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the physiological role of PPAR! is to enhance epidermal differentiation (Schmuth et al 
2004). It is therefore possible that, in psoriasis, suppression of terminal differentiation 
and the block in skin barrier repair may in fact lead to the non-terminated upregulation 
of PPAR! in the upper spinous layer of the epidermis (Romanowska et al 2010), which 
in turn would explain the chronic nature of the disease clinically. Therefore, genetic 
variants that block terminal differentiation would be expected to enhance psoriasis risk. 
This is exactly what appears to be the case with the LCE3 gene variants (de Cid et al 
2009).  The end result is a feedback loop resulting in the chronic and persistent course 
of psoriasis, as summarised in figure 4.2.    
 
 
Figure 4.2: Disease Signalling Pathways Mediated By PPAR!. Schematic diagram 
showing the PPAR!/STAT3/IL-1 pathway elucidated as a result of this work, showing 
the role of PPAR! in maintaining psoriasis and the role of the genomic risk alleles. Also 
shown is a list of factors known to trigger disease flares and also activate PPAR!. 
Modified from (Romanowska et al 2010). 
 
 
 
97 
4.5 Applicability Of The Current Model For Translational Research 
 
When considering any in vivo model of a complex polygenic disease, it is important to 
remember that in any transgenic system, one can only manipulate a set number of 
variables within the system. The majority of in vivo models are designed so as to allow 
dissection of the role of particular pathways in a larger system. Given previous data 
generated by our lab on the role of PPAR! in psoriasis and epidermal development (al 
Yacoub et al 2008, Romanowska et al 2008), it was important to observe the possible 
effects of overexpressing PPAR! in an in vivo model, to thus obtain a better 
understanding of the other roles of this protein. The fact that it is the full length human 
form of the protein expressed in this model adds relevance as it will allow for the 
development of targeted treatments. Additionally, the system created in this model is 
fully reversible, thus upon cessation of systemic induction via GW501516 containing 
diet, the phenotype of the mice returns to normal. This is an important feature, as it not 
only shows that continuous activation of PPAR! is required to maintain disease activity 
but also indicates that the model will be responsive to treatments. Therefore, this model 
exhibits a number of advantages to study pathways and treatments for psoriasis when 
compared to the human skin graft approaches, as follows. The need for skin biopsies is 
central to the success of human-skin graft models, which are limited, therefore leading 
to low throughput. Also, skin graft can take a number of weeks to “settle” after being 
grafted to the mice. In addition, the mice that are commonly used for such approaches 
are immunocompromised, which directly contradicts the strong immune component of 
the disease. In addition, skin-graft approaches only develop some of the features of 
psoriasis, and usually need a stimulus to achieve this. Therefore, a model that focuses 
on a central mediator is better suited to study the pathogenesis of psoriasis, such as the 
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PPAR! model, which as previously discussed, recapitulates many of the key aspects of 
psoriasis. 
 
4.6 Overlap Between Psoriasis And Metabolic Disease 
 
It is becoming increasingly apparent that there is a significant clinical overlap between 
psoriasis and metabolic syndrome, which includes obesity, diabetes and cardiovascular 
disease (Azfar and Gelfand 2008). A patient is considered to have metabolic syndrome 
if they display at least 3 of the following conditions: abdominal obesity, elevated serum 
triglycerides, low HDL cholesterol, elevated blood pressure or elevated fasting glucose 
(Azfar and Gelfand 2008). The clinical features that most often correlate with psoriasis 
are hypertriglyceridemia and abdominal obesity. Interestingly, obesity may occur before 
the onset of psoriasis and is considered a risk factor for the disease. In addition, 
increasing BMI (Body Mass Index) correlates with severity of psoriatic disease (Azfar 
and Gelfand 2008, Naldi et al 2005). An important feature of psoriasis is the elevation 
of Th1 cytokines, which chronically is also important in the pathophysiology of 
metabolic syndrome. On the other hand, inflammatory molecules and hormones 
produced as a result of obesity, diabetes etc, may also contribute to the pathogenesis of 
psoriasis. Insulin resistance, a feature that both psoriasis and metabolic syndrome share 
may also be mediated by inflammatory cytokine produced as a result of either 
condition, predominantly TNF. It is proposed that TNF may lead to insulin resistance 
by inhibiting the tyrosine kinase associated with the insulin receptor or via the 
activation of PPAR! (Azfar and Gelfand 2008, Di-Poi et al 2003, Tan et al 2001). As 
discussed previously, PPAR! promotes epidermal proliferation, modulates adipogenesis 
and glucose metabolism, and is highly expressed in psoriatic lesions.  PPAR! plays a 
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role in the fatty acid catabolism in muscle and adipose tissue, further supporting a role 
in metabolic disease.  
 
4.7 Implications For PPAR Agonists In Metabolic Disease 
 
To date no PPAR! agonists have been approved for clinical use. One clinical study has 
been performed using GW501516 to examine its effectiveness at treating obesity and 
symptoms associated with metabolic syndrome. This short-term study, lasting only 2 
weeks, found that GW501516 reduced fasting plasma triglycerides, apolipoprotein B, 
LDL cholesterol, and insulin (Riserus et al 2008). In addition, liver fat content and 
urinary isoprostanes were also reduced. In vivo, weight loss and “leanness” of PPAR! 
mice being treated with GW501516 compared to control transgenics is also apparent. 
This could be explained by the other known functions of PPAR! such as fatty acid 
oxidation. During prolonged periods of treatment with GW501516 (>3 weeks), it is 
possible that GW501516 is activating endogenous PPAR! in murine tissues and this 
causes the weight loss observed since the transgene is only expressed in skin. Despite 
showing clinical effectiveness, treating patients with a PPAR! agonist should be met 
with caution. Based on the present data, one may speculate that prolonged treatment 
with GW501516 could precipitate psoriasis as a side effect in genetically predisposed 
individuals.  
 
4.8 Activation Of STAT3 
 
Aside from the apparent increase STAT3 activation in the skin of induced PPAR! mice, 
one observation made in this thesis was the differential phosphorylation of two distinct 
bands as detected by western blot (Figure 3.10), corresponding to two separate isoforms 
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of STAT3, STAT3# (89 kDa) and STAT3" (80 kDa) (Caldenhoven et al 1996). These 
isoforms are generated by alternative splicing at exon 23, which results in the deletion 
of the first 55 nucleotides of exon 23 and results in a frameshift that introduces 7 
alternative amino acids followed by a stop codon (Yoo et al 2002). This alternative 
splicing results in either a full-length isoform (STAT3#), or a truncated isoform lacking 
the C-terminal activation domain (STAT3"), which respectively have distinct roles in 
development and inflammation. The truncated isoform of STAT3, despite lacking the 
C-terminal domain, still retains the phosphorylation site at Tyr705, which is key in its 
activation (Maritano et al 2004, Yoo et al 2002). Ablation of STAT3# results in mice 
that survive until 24hr after birth, which suggests that STAT3" partially compensates 
for the embryonic lethality that arises from complete STAT3 deletion (Maritano et al 
2004). It has been suggested that STAT3" can act in a dominant negative respect, 
however more evidence is emerging that STAT3" may have distinct functions from 
STAT3#. The differences in phenotype between the two strains of mice can be 
attributed to the differing roles of the STAT3 isoforms as these mice were generated on 
the same CB6F1 (C57BL/6 ' BALB/cAn) background (Maritano et al 2004). Maritano 
and colleagues showed that STAT3" is able to induce acute phase genes in the liver of 
mice challenged with LPS but unable to sustain their induction. Similarly, ablation of 
STAT3" results in an increase in IL-6 serum levels in response to LPS and in 
macrophages from these mice results in more TNF and IL-6 produced than compared to 
control macrophages following treatment with LPS and IFN-$ (Maritano et al 2004, 
Yoo et al 2002). STAT3#-deficient macrophages on the other hand, produced far less 
TNF and IL-6 in response to LPS than those cells lacking both isoforms. These data 
suggest that STAT3# in fact may be involved in the pro-inflammatory changes in 
PPAR! transgenic mice as well as in psoriasis where differential regulation of both 
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isoforms has not been examined to date. Thus, it is noteworthy that PPAR! activation 
induces specific STAT3# phosphorylation.  
 
4.9 Mechanism Of STAT3 Activation 
 
In PPAR! transgenic mice, STAT3 is highly overexpressed, replicating results 
previously reported for psoriasis (Sano et al 2005). This suggests that STAT3 is a target 
for PPAR!. However it is not a direct target gene as PPAR! is unable to phosphorylate 
STAT3 directly as PPAR! possesses no intrinsic tyrosine kinase activity.  Previous 
studies by John Foerster’s group revealed that HB-EGF and TGF-# are upregulated in 
psoriasis (Romanowska et al 2008). These two EGF-family ligands that are upregulated 
in psoriasis, may be responsible for the phosphorylation and activation of STAT3, 
which aids in the explanation of why the development of the psoriasis phenotype 
observed in PPAR! mice is not fully inhibited by the use of the JAK2 inhibitor, 
WP1066. Another potential kinase that may play a role in the activation of STAT3 is 
PTK6, which is upregulated in both psoriasis and PPAR! transgenic mice 
(Romanowska et al 2010). These data suggest that at least two additional kinase 
pathways are capable of contributing to the activation of STAT3. Finally, in terms of 
the overlap between psoriasis and metabolic syndrome, it is noteworthy that the leptin 
receptor can also trigger STAT3 phosphorylation (Maritano et al 2004). Thus, in the 
context of obesity of lipid derangement increased circulating leptin can converge on the 
same pathway. 
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4.10 STAT3 Immunofluorescence 
 
Immunofluorescence protocols were established in the course of this work to examine 
murine skin samples since the STAT3 antibody available had well documented use in 
immunofluorescence (Bauer and Patterson 2006, Ernst et al 2009, Tripathi and McTigue 
2008). This antibody was also used for western blotting and yielded highly specific 
results, confirming antibody specificity. For further independent confirmation, we 
employed the use of a blocking peptide that inhibited the binding of phospho-STAT3 
antibody to the antigen. This method was selected as the blocking peptide is highly 
specific (http://www.cellsignal.com/products/1195.html). In terms of localisation, the 
localisation of phospho-STAT3 observed in our samples showed localisation to the 
upper layers of the epidermis with highly specific nuclear staining very consistent with 
that previously reported for psoriatic lesional skin (Sano et al 2005).  
 
4.11 Inhibition Of STAT3 With WP1066, A Specific JAK2 Antagonist. 
 
Due to the discovery that STAT3 is highly overexpressed and activated in PPAR! mice 
induced with GW501516, the possibility of inhibiting the activation of STAT3 and the 
effect of this on the psoriatic phenotype observed in PPAR! mice was investigated. 
JAK2 is the major tyrosine kinase receptor that phosphorylates STAT3 causing it to be 
activated in response to stimulation by growth factors and various cytokines. We 
initially identified a JAK2 inhibitor that is highly specific and had been tested 
previously on mice of the same genetic background, C57Bl/6j. Thus, we had previously 
tested this JAK2 antagonist, AG490, but found that it had no detectable effect on the 
phenotype (unpublished observation), despite this compound being documented as 
having inhibitory effects in vitro (Iwamaru et al 2007, Meydan et al 1996). However, 
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using the structure of AG490 as a basis, Iwamaru and colleagues developed subsequent 
compounds that afforded the same inhibitory action observed in vitro that would be 
bioavailable in vivo, including WP1066 (Iwamaru et al 2007).  
 
One limiting aspect of STAT3 inhibition is toxicity. Previous studies using the same 
transgenic mouse strain, C57Bl/6j mice, had shown that mice could tolerate a dosage of 
20 mg/kg via intraperitoneal injection; approximately equivalent to 400 (g per mouse 
(Kong et al 2009), assuming approximate weight is 20g. The dosage selected for the 
present studies therefore was that of 75 µl injections of 1.25µg/µl WP1066 dissolved in 
DMSO/PEG 300 (80/20) 3 times per week, resulting in a total weekly dose of almost 
300 (g. This dose ensured sub-toxic levels even allowing for variations in weight. 
Despite all these precautions, after two weeks of treatment, mice began to show signs of 
toxicity. It appears that the serum concentration of WP1066 may have increased to 
levels not tolerated by the mice and began to exhibit symptoms of toxicity (Kong et al 
2008). However, it does not appear that toxicity caused by WP1066 is responsible for 
the inhibition of phenotype development because there is partial inhibition of full 
phenotype observed before the onset of toxicity. 
 
This toxicity caused by JAK2 inhibition is likely due to heightened sensitivity toward 
apoptosis. Iwamaru and colleagues found that WP1066 treatment of malignant glioma 
cells with WP1066 resulted in activation of Bax, suppression of c-myc, Bcl-XL and 
Mcl-1 expression, and induced apoptosis (Iwamaru et al 2007). Similarly, WP1066 
treatment was reported to reverse immune tolerance and inhibit cancer cell growth via 
the induction of apoptosis (Hussain et al 2007). As in the other study, acute and chronic 
toxicity are observed in vivo following increasing doses of WP1066, with mice 
exhibiting symptoms of diarrhoea, frequent urination and in chronic cases, adhesion of 
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the mouse intestine to the abdominal wall and muscle (Kong et al 2008). In terms of 
toxicity development over time, WP1066 treatment was shown to inhibit STAT3 for up 
to 3 weeks post injection (Iwamaru et al 2007). Importantly, WP1066 is highly specific 
for JAK2, suggesting that WP1066 related toxicity is unlikely to be mediated by off-
target effects (Iwamaru et al 2007).  
 
Although the partial disease reversal confirms a role of STAT3 downstream of PPAR!, 
it is not the only factor mediating disease development. Firstly, as mentioned, the onset 
of the psoriasis phenotype is not fully, but only partially inhibited in mice treated with 
WP1066. Secondly, overexpression of STAT3 alone causes a less widespread psoriasis-
like phenotype with a longer latency (Romanowska et al 2010, Sano et al 2005). Despite 
not being the sole mediator of the psoriasis phenotype in PPAR! transgenic mice, there 
is no doubt that STAT3 does play a role in the pathogenesis of psoriasis. 
 
4.12 STAT3 And The “Anti Inflammatory Response”. 
 
As previously described, the interferon response genes are downregulated in PPAR! 
mice but upregulated in psoriasis patients. STAT3 was previously shown to cause the 
same set of transcriptional change, termed “inflammatory response” (Murray, 2006), 
suggesting that due to its massive overexpression in our model, it may contribute to the 
downregulation of these genes as well. In line with this, figure 4.3 shows the interferon 
response genes downregulated in PPAR! mice that have been induced with GW501516 
versus control transgenics (white columns). Indeed, downregulation of the most 
strongly repressed transcript, IFI27, was only partially reversed upon inhibition of 
STAT3 signalling with WP1066 treatment, confirming that downregulation of IFN-
alpha response genes is indeed at least partly mediated by STAT3 activation.  
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Figure 4.3: Interferon Response Gene Expression In Psoriasis Vs PPAR! Transgenic 
Mice. Diagram showing relative expression of interferon response genes in 4 different 
data sets. Dark grey columns represent data taken from (Dauer et al 2005), white 
columns represent data from GW501516 fed PPAR! mice vs control treated mice, light 
grey and black columns represent data from lesional vs. non-lesional skin from 
psoriasis patients in the GSE14905 and the GAIN datasets. (Modified from 
(Romanowska et al 2010). 
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4.13 Concluding Remarks And Possibilities For Future Work 
 
This thesis details the generation of an in vivo model of the human disease psoriasis. 
These results showed that overexpression of PPAR!, a transcription factor, produced a 
fully reversible in vivo model that reproduces many of the characteristics associated 
with psoriasis. This model will prove useful in elucidating the signalling pathways that 
PPAR! regulates. In addition, it will also be useful for the development of a PPAR! 
targeted treatment for psoriasis. For the full report on this model, please see 
(Romanowska et al 2010). 
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